Skip to main content

N

  • Chapter
  • 228 Accesses

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ray JE, Day RO (1984) J Chromatogr 336:234–238

    PubMed  CAS  Google Scholar 

  2. Friedel HA, Todd PA (1988) Nabumetone: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases, Drugs 35:504–524

    PubMed  CAS  Google Scholar 

  3. Boyle EA, Freeman PC, Mangan FR, Thomson MJ (1982) Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-bu-tan-2-one): a new anti-inflammatory agent, J Pharm Pharmacol 34:562–569

    PubMed  CAS  Google Scholar 

  4. Mangan FR (1985) A review of the pharmacology of nabumetone, Royal Soc Med Int Congress and Symp Series 69:5–14

    CAS  Google Scholar 

  5. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of aspirin-like drugs, Nature (New Biol) 231:232–235

    CAS  Google Scholar 

  6. Vane JR (1987) The evolution of non-steroidal anti-inflammatory drags and their mechanism of action, Drugs 33(Suppl 1): 18–27

    PubMed  CAS  Google Scholar 

  7. Mangan FR, Flack JD, Jackson D (1987) Preclinical overview of nabumetone pharmacology, bioavailability, metabolism and toxicology, Am J Med 86(Suppl 4B):6–10

    Google Scholar 

  8. DeardenJC, Nicholson RM (1984) Correlation between gastric irritancy and anti-inflammatory activity of non-steroidal anti-inflammatory drugs, J Pharm Pharmacol 36:713–715

    Google Scholar 

  9. Huston GJ (1985) Local buccal mucosal effects of aspirin, naproxen, and nabumetone, Royal Soc Med Int Congress Symp Series 69:43–46

    Google Scholar 

  10. Lussier A, LeBel E (1987) Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin and nabumetone, Am J Med 83(Suppl 4B): 15–18

    PubMed  CAS  Google Scholar 

  11. Garner A (1977) Mechanisms of action of aspirin on the gastric mucosa of the guinea pig, Acta Physiol Scand:101-110

    Google Scholar 

  12. Jackson RE, Mitchell FN, Brindley DA (1987) Safety evaluation of nabumetone in United States clinical trials, Am J Med 83(Suppl 4B):115–120

    CAS  Google Scholar 

  13. Jenner PN, Johnson ES (1987) Review of the experience with nabumetone in clinical trials outside the United States, Am J Med 83(Suppl 4B): 110–114

    PubMed  CAS  Google Scholar 

  14. Dandona P, Jeremy J Y (1990) Nonsteroidal anti-inflammatory drag therapy and gastric side effects: does nabumetone provide a solution? Drags 40(Suppl 5): 16–24

    CAS  Google Scholar 

  15. Freeman AM, Undre NA, Thawley AR, Golding DN (1985) Plasma and synovial fluid concentrations of nabu-metone and BRL 10720 in patients given nabumetone, Royal Soc Med Int Congress Symp Series 69:37–42

    Google Scholar 

  16. Brobyn RD (1987) Nabumetone in the treatment of active adult rheumatoid arthritis. Am J Med 83(Suppl 4B):50–54

    PubMed  CAS  Google Scholar 

  17. Appelrouth DJ, Bairn S, Chang RW, Cohen MH, Englund DW, Germain BF, Hartmann SS, Jaffer A, Mullen BJ, Smith FE (1987) Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults, Am J Med 83(Suppl 4B):78–81

    PubMed  CAS  Google Scholar 

  18. Pisko EJ, Bockow BI, Box P, Brodsky AL, Burch FX, Collins RL, Fleischmann RM, Keller MI, Lipani JA, Poiley JE (1987) Six-month multicenter study comparing nabumetone and naproxen in the treatment of osteoarthritis, Am J Med 83(Suppl 4B):86–91

    PubMed  CAS  Google Scholar 

  19. Carle WK, Rotman H (1985) General practice study of nabumetone and indomethacin in patients with osteoarthritis, Royal Soc Med Int Congress Symp Series 69:139–148

    Google Scholar 

  20. Wade AG, Fletcher DM (1985) Comparison of nabumetone and indomethacin in the treatment of patients in general practice with osteoarthritis, Royal Soc Med Int Congress Symp Series 69:149–160

    Google Scholar 

  21. Von Schrader HW, Buscher G, Dierdorf D, Mugge H, Wolf D (1983) Nabumetone — a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses, Int J Clin Pharmacol Ther Tox 21:311–321

    Google Scholar 

  22. Nandi KL, Corless D, Undre NA, Thawley AR (1985) A study of the pharmacokinetics, effectiveness, and tolerance of nabumetone, a novel anti-inflammatory drug, in elderly patients, Royal Soc Med Int Congress Symp Series 69:163–172

    Google Scholar 

  23. McMahon FG, Vargas R, Ryan JR, Fitts DA (1987) Nabumetone kinetics in young and elderly patients, Am J Med 83(Suppl 4B):92–95

    PubMed  CAS  Google Scholar 

  24. Bourke B, Undre NA, Thawley AR (1985) An investigation into the penetration of nabumetone and its metabolites into synovial fluid in patients with rheumatoid arthritis, Royal Soc Med Int Congress Symp Series 69:31–35

    Google Scholar 

  25. Jackson D, Hardy TL, Langley PF, von Schrader HW (1985) Pharmacokinetic, toxicological, and metabolic studies with nabumetone, Royal Soc Med Int Congress Symp Series 69:15–27

    CAS  Google Scholar 

  26. Boelaert JR, Jonnaert HA, Daneels RF, Schurgers ML, Thawley AR, Undre NA, Cooper DL (1987) Nabumetone pharmacokinetics in patients with varying degrees of renal impairment, Am J Med 83(Suppl 4B): 107–109

    PubMed  CAS  Google Scholar 

  27. Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR (1984) Metabolism of nabumetone (BRL 14777) by various species including man, Xenobiotica 14:327–337

    PubMed  CAS  Google Scholar 

  28. Rainsford KD (1984) Side effects of anti-inflammatory/ analgesic drugs. Epidemiology and gastro-intestinal tract, Trends Pharmacol Sci 5:156–159

    CAS  Google Scholar 

  29. O’Brien WM, Bagby GF (1985) Rare adverse reactions to nonsteroidal anti-inflammatory drugs, J Rheumatol 12:13–20, 347-353, 562-567, 785-790

    PubMed  Google Scholar 

  30. Rainsford KD, Velo GP (Hrsg.) (1984) Side effects of anti-inflammatory/analgesic drugs, Raven Press, New York

    Google Scholar 

  31. Rainsford KD, Velo GP (Hrsg.) (1987) Side effects of anti-inflammatory drugs, Bd. I und II, MTP Press, Lancaster

    Google Scholar 

  32. Rainsford KD (1987) Toxicity of currently used anti-inflammatory and anti-rheumatic drugs. In: Lewis AJ, Furst DE (Hrsg.) Newer anti-inflammatory drugs, Dekker, New York, S.215–244

    Google Scholar 

  33. Rainsford KD (1988) Current concepts of the mechanisms of side effects of nonsteroidal anti-inflammatory drugs as a basis for establishing research priorities. An experimentalist’s view, J Rheumatol 15(Suppl. 17):63–70

    Google Scholar 

  34. Ishikawa H, Tabusa F, Miyamoto H, Kano M, UedaH, Tamaoka H, Kazuyuki N (1989) Chem Pharm Bull 37:2103–2108

    PubMed  CAS  Google Scholar 

  35. Akamatsu H, Sasaki H, Kurokawa I, Nishijima S, Asada Y und Niwa Y (1995) Effect of Nadifloxacin on Neutrophil Functions J of Int Med Res 23/1:19–26

    CAS  Google Scholar 

  36. Vogt K, Hahn H, Hermann J, Haustein UF, Blume U, Gollnick H und Orfanos CE (1995) Antimicrobial Evaluation of Nadifloxacin (OPC-7251), a New Topical Quinolone, in Acne Vulgaris Drugs 49(Suppl 2):266–268

    CAS  Google Scholar 

  37. Nishijima S, Namura S, Akamatsu H, Kawai S, Asada Y, Kawabata S und Fujita M (1995) In vitro activity of Nadifloxacin against both Methicillin-Susceptible and-Rcsistant Clinical Isolates of Staphylococcus aureus from Patients with Skin Infections Drugs 49(Suppl 2):230–232

    PubMed  CAS  Google Scholar 

  38. Daten der Firma Galderma (s. Fachinformation zu Nadifloxacin)

    Google Scholar 

  39. Bojar RA, Hittel N, Cunliffe WJ, Holland KT (1995) Direct Analysis of Resistance in the Curaneous Microflora during Treatment of Acne Vulgaris with Topical 1 % Nadifloxacin and 2 % Erythromycin Drugs 49(Suppl 2): 164–167

    PubMed  CAS  Google Scholar 

  40. Takahashi N, Shibahara T, Shiragiku T, Kanbe T, Kanbe K, Sugawara M, Yamashita S (1995) Reduction of in vitroClastogenicity induced by the mixture of optical isomers of nadifloxacin during storage. Arzneimittelforschung 45/2, 195–197

    Google Scholar 

  41. Björk I, Lindahl V (1982) Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 48:161–182

    PubMed  Google Scholar 

  42. Oosta GM, Gardner WT, Beeler DL, Rosenberg RD (1981) Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 78:829–833

    PubMed  CAS  Google Scholar 

  43. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccaride with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Bio-phys Res Commun 116:492–499

    CAS  Google Scholar 

  44. Cerskus AL, Birchall KJ, Ofosu FA, Hirsh J, Blajchman MA (1984) Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. Canad J Biochem Cell Biol 62:975–983

    CAS  Google Scholar 

  45. Abildgaard U (1993) Heparin/Low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 23(suppl 1):103–106

    PubMed  CAS  Google Scholar 

  46. Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ (1983) Heparin and a low weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 30:219–224

    PubMed  CAS  Google Scholar 

  47. Fareed J, Walenga JM, Williamson K, Martine-Emanuele R, Kumar A, Hoppensteadt DA (1985) Studies on the anti-thrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost 11:56–74

    PubMed  CAS  Google Scholar 

  48. Doutremepuich C, Gestreau JL, Maury MO, Quilichini R, Boisseau MR, Toulemonde F, Vairel E (1983) Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostasis 13:109–112

    PubMed  CAS  Google Scholar 

  49. Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D (1984) Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hémat 26:267–275

    CAS  Google Scholar 

  50. Weichen W, Breddin HK (1988) Effect of low-molecular weight heparins on laser-induced thrombus formation in rat mesenteric vessels. Haemostasis 18(suppl 3):55–63

    Google Scholar 

  51. Brace L, Fareed J (1985) An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 11:190–198

    PubMed  CAS  Google Scholar 

  52. Heinrich D, Görg T, Schulz M (1988) Effects of unfrac-tionated and fractionated heparin on platelet function. Haemostasis 18, suppl. 3:48–54

    PubMed  CAS  Google Scholar 

  53. Harenberg J, Würzner B, Zimmermann R, Schettler G (1986) Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 44:549–554

    PubMed  CAS  Google Scholar 

  54. (1995) Fraxiparine®. Nadroparin Calcium PH. Eur. Technical Brochure. Sanofi Pharma

    Google Scholar 

  55. Kakkar VV, Murray WJG (1985) Efficacy and safety of low-molecular weight heparin (CY 216) in preventing postoperative venous thrombo-embolism: a cooperative study. Brit J Surg 72:786–791

    PubMed  CAS  Google Scholar 

  56. The European Fraxiparin Study Group (EFS). Publishing Commitee: Encke A, Breddin HK, Koppenhagen K, Klempa I et al. (1988) Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein, thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Br J Surg 75:1058–1063

    Google Scholar 

  57. Aoyama T, Okutome T, Nakayama T, Yaegashi T, Matsui R, Nunomura S, Kurumi M, Sakurai Y, Fujii S (1985) Chem Pharm Bull 33:1458–1471

    PubMed  CAS  Google Scholar 

  58. Arakawa K, Kurotori M, Sugiyama S, Kurumi M, Aoyama T (1985) Yakugaku Zasshi 105:512–516

    PubMed  CAS  Google Scholar 

  59. Aoyama T, Sasaki H, Shibuya M, Suzuki Y (1985) Chem Pharm Bull 33:2142–2144

    PubMed  CAS  Google Scholar 

  60. Fuji S, Hitomi Y (1981) Biochim Biophys Acta 661:342–345

    Google Scholar 

  61. Kurotori M, Arakawa K, Sugiyama S, Kurumi M, Aoyama T (1985) Yakugaku Zasshi 105:470–474

    PubMed  CAS  Google Scholar 

  62. Ono H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Kiriyama S, Sobajima H (1990) Dig Dis Sci 35:787–792

    PubMed  CAS  Google Scholar 

  63. Mar 31, S 1730

    Google Scholar 

  64. Drugs Fut (1985) 10(7):565-569

    Google Scholar 

  65. Nestor JJ Jr (1984) Development of agonistic LHRH and its analogs, Lancester, MTP Press 3–10

    Google Scholar 

  66. Henzel MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J (1988) Administration of nasal nafarelin as compared with oral danazol for endometrio-sis, New England J of Medicine 318(8):485–489

    Google Scholar 

  67. Hoffman PG, Henzel MR, Chaplin MD, Nerenberg CA (1987) Clinical development of Nafarelin acetate phase I and phase II studies; J Androl 8:17–22

    Google Scholar 

  68. Drugs Fut (1976) 1(7):339-353

    Google Scholar 

  69. Moody DE, Reddy JK (1978) The hepatic effects of hypo-lipidemic drugs (clofibrate, nafenopin, fibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-as-sociated enzymes. Am J Pathol 90:435–450

    PubMed  CAS  Google Scholar 

  70. Levine WG, Braunstein HR, Meijer DK (1975) Effect of nafenopin (SU-13,437) on liver function: mechanism of choleretic effect. Naunyn Schmiedebergs Arch Pharmacol 290:221–234

    PubMed  CAS  Google Scholar 

  71. Meijer DK, Bognacki J, Levine WG (1975) Effect of nafenopin (SU-13,437) on liver function: influence on the hepatic transport of organic anions. Naunyn Schmiedebergs Arch Pharmacol 290:235–250

    PubMed  CAS  Google Scholar 

  72. Reddy JK, Rao MS (1977) Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J Natl Cancer Inst 59:1645–1550

    PubMed  CAS  Google Scholar 

  73. Izquierdo A, Bosch E, Rodrigo V (1982) Talanta 29:1125–1129

    PubMed  CAS  Google Scholar 

  74. Clarke EGC (1975) Isolation and Identification of Drugs, Vol. 2, 1. Aufl., The Pharmaceutical Press, London, S.1066

    Google Scholar 

  75. Kracmar J, Kracmarova J (1979) Pharmazie 34:27–32

    PubMed  CAS  Google Scholar 

  76. Bosch E, Cassasas E, Izquierdo A, Roses M (1984) Anal Chem 56:1422–1428

    CAS  Google Scholar 

  77. Klein-Soyer C, Bloy C, Archiproff G, Beretz A, Cazenave JP (1995) Naftazone accelerates human saphenous vein endothelial cell proliferation in vitro. Nouv Rev Fr Hemat-ol 37:187–192

    CAS  Google Scholar 

  78. Berson I (1977) Etude clinique d’un nouveau veinotrope: le mediaven (naftazone). Schweiz Rundsch Med Prax 66:180–181

    PubMed  CAS  Google Scholar 

  79. Meszaros T (1977) Plethysomographische Untersuchung von Beinbeschwerden unter Einnahme von Ovulations-hemmern und ihre Behandlung mit Mediaven (DCI Naftazone). Schweiz Rundsch Med Prax 66:209–213

    PubMed  CAS  Google Scholar 

  80. Drug Fut (1987) 12:31-33

    Google Scholar 

  81. Kutscher B, Engel J, Fleischhauer I, Niebch G (1993) Arch Pharm 326:803–806

    CAS  Google Scholar 

  82. Sponer G, Borbe HO, Muller-Beckmann B, Freud P, Jakob B (1992) Naftopidil, a new adrenoceptor blocking agent with Ca2+-antagonistic properties: interaction with adreno-

    Google Scholar 

  83. Alarayyed NA, Cooper MB, Prichard BN, Betteridge DJ, Smith CC (1997) In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br J Clin Pharmacol 43:415–420

    PubMed  CAS  Google Scholar 

  84. Pescalli N, Sala V, Spooner G, Ceserani R (1996) Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats. Pharmacol Research 34:121–124

    CAS  Google Scholar 

  85. Grundke M, Himmel HM, Wettwer E, Borbe HO, Ravens U (1991) Characterization of Ca2+ antagonistic effects of three metabolites of the new antihypertensive agent naftopidil. J Cardiovasc Pharmacol 18:918–925

    PubMed  CAS  Google Scholar 

  86. Takeda T, Kouno M, Iimimur O, Yoshinaga K, Kuramoto K (1992) The study of clinical effect and optimal dose of naftopidil (KT-611) in essential hypertension. Rinsho Iya-ku 8(Suppl 3):65–88

    Google Scholar 

  87. Takeda T, Kouno M, Iimimira O, Yoshinaga K, Kuramoto K (1992) The clinical effect of naftopidil (KT-611) in the long-term treatment of essential hypertension. Rinsho Iya-ku 8(Suppl 3): 123–145

    Google Scholar 

  88. Yasuda K, Amanishi T, Toho M, Nagashim K, Akimoto S, Shimazaki J (1994) Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 25:46–52

    PubMed  CAS  Google Scholar 

  89. Peter G, Niebch G, Locher M, Borbe HO (1991) Pharma-cokinetic fate of the novel antihypertensive drug naftopidil. Arzneimittel-Forschung 41:924–931

    PubMed  CAS  Google Scholar 

  90. Farthing MJG, Alstead EM, Abrams SML, Haug G, Johnston A (1994) Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgraduate Med J 70:363–366

    CAS  Google Scholar 

  91. Drugs Fut (1984) 9(7):518-519

    Google Scholar 

  92. Hermann EC, Lee KT, Myers MJ (duPont de Nemours, E.I. and Co.) Eur Pat Appl 39,066; Jpn K 81,167,678; US K4,322,426; zit. aus Lit.1

    Google Scholar 

  93. Gal TJ, DiFazio CA (1986) Prolonged antagonism of opi-oid action with intravenous nalmefene in man. Anesthe-siology 64:175–180

    CAS  Google Scholar 

  94. Konieczko KM, Jones JG, Barrowcliffe MP, Jordan C, Altman DG (1988) Antagonism of morphine-induced respiratory depression with nalmefene. Br J Anaesth 61:318–323

    PubMed  CAS  Google Scholar 

  95. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D (1987) Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 27:233–239

    PubMed  CAS  Google Scholar 

  96. Michel ME, Bolger G, Weissman BA (1985) Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7:175–177

    PubMed  CAS  Google Scholar 

  97. Feldman M, Moore L, Walsh JH (1985) Effect of oral nalmefene, an opiate-receptor antagonist, on meal-stimulated gastric acid secretion and serum gastrin concentration in man. Regul Pept 11:245–250

    PubMed  CAS  Google Scholar 

  98. Graham SH, Shimizu H, Newman A, Weinstein P, Faden AI (1993) Opioid receptor antagonist nalmefene stereo-specifically inhibits glutamate release during global cerebral ischemia. Brain Res 632:346–350

    PubMed  CAS  Google Scholar 

  99. Gal TJ, DiFazio CA, Dixon R (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 40:537–542

    PubMed  CAS  Google Scholar 

  100. Dixon R, Howes J, Gentile J, Hsu HB, Hsiao J, Garg D, Weidler D, Meyer M, Tuttle R (1986) Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 39:49–53

    PubMed  CAS  Google Scholar 

  101. Glass PS, Jhaveri RM, Smith LR (1994) Comparison of potency and duration of action of nalmefene and nal-oxone. Anesth Analg 78:536–541

    PubMed  CAS  Google Scholar 

  102. Kaplan JL, Marx JA (1993) Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med 22:187–190

    PubMed  CAS  Google Scholar 

  103. Stone NN (1994) Nalmefene in the treatment of interstitial cystitis. Urol. Clin North Am 21:101–106

    CAS  Google Scholar 

  104. (1995) Product Information Revex®, Nalmefene Ohmeda Pharmaceutical Products, Liberty Corner NJ

    Google Scholar 

  105. Monroe EW (1989) Efficacy and safety of nalmefene in patients with severe pruritis caused by chronic urticaria and atopic dermatitis [see comments]. J Am Acad Dermat-ol 21:135–136

    CAS  Google Scholar 

  106. Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE (1991) Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther 49:300–306

    PubMed  CAS  Google Scholar 

  107. Portoghese PS, Sultana M, Nagase H, Takemori AE (1988) J Med Chem 31:281–282

    PubMed  CAS  Google Scholar 

  108. Calcagnetti DJ, Holtzman SG (1991) Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol Biochem Behav 38:185–190

    PubMed  CAS  Google Scholar 

  109. Portoghese PS, Nagase H, MaloneyHuss KE, Lin CE, Takemori AE (1991) Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole. J Med Chem 34:1715–1720

    PubMed  CAS  Google Scholar 

  110. Shah S, Davis T, Yoburn BC (1994) The effect of naltrindole on spinal and supraspinal delta opioid receptors and analgesia. Life Sci 55:1451–1458

    PubMed  CAS  Google Scholar 

  111. Stapelfeld A, Hammond DL, Rafferty MF (1992) Antino-ciception after intracerebroventricular administration of naltrindole in the mouse. Eur J Pharmacol 214:273–276

    PubMed  CAS  Google Scholar 

  112. Suzuki T, Tsuji M, Mori T, Misawa M, Nagase H (1995) Effect of naltrindole on the development of physical dependence on morphine in mice: a behavioral and biochemical study. Life Sci 57:PL247–252

    PubMed  CAS  Google Scholar 

  113. Kitchen I, Pinker SR (1990) Antagonism of swim-stress-induced antinociception by the delta-opioid receptor antagonist naltrindole in adult and young rats. Br J Pharmacol 100:685–688

    PubMed  CAS  Google Scholar 

  114. Krishnan Sarin S, Jing SL, Kurtz DL, Zweifel M, Portoghese PS, Li TK, Froehlich IC (1995) The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology Berl. 120:177–185

    PubMed  CAS  Google Scholar 

  115. Leventhal L, Kirkham TC, Cole JL, Bodnar RJ (1995) Selective actions of central mu and kappa opioid antagonists upon sucrose intake in sham-fed rats. Brain Res 685:205–210

    PubMed  CAS  Google Scholar 

  116. Kelley AE, Bless EP, Swanson CJ (1996) Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J Pharmacol Exp Ther 278:1499–1507

    PubMed  CAS  Google Scholar 

  117. Piepponen TP, Ahtee L (1995) Effects of selective opioid receptor antagonists on morphine-induced changes in striatal and limbic dopamine metabolism. Pharmacol To-xicol 77:204–208

    CAS  Google Scholar 

  118. Ossipov MH, Kovelowski CJ, Vanderah T, Porreca F (1994) Naltrindole, an opioid delta antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat. Neurosci Lett 181:9–12

    PubMed  CAS  Google Scholar 

  119. Funada M, Schutz CG, Shippenberg TS (1996) Role of delta-opioid receptors in mediating the aversive stimulus effects of morphine withdrawal in the rat. Eur J Pharmacol 300:17–24

    PubMed  CAS  Google Scholar 

  120. Heidbreder C, Shoaib M, Shippenberg TS (1996) Differential role of delta-opioid receptors in the development and expression of behavioral sensitization to cocaine. Eur J Pharmacol 298:207–216

    PubMed  CAS  Google Scholar 

  121. Menkens K, Bilsky EJ, Wild KD, Portoghese PS, Reid LD, Porreca F (1992) Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole. Eur J Pharmacol 219:345–346

    PubMed  CAS  Google Scholar 

  122. Mousseron M (1959) US Pat 2882201, zit. nach CA (1959) 53:170841

    Google Scholar 

  123. MI 12

    Google Scholar 

  124. Wenner W (1950) J Org Chem 15:548

    CAS  Google Scholar 

  125. Southwick PL, Pursglove WA, Pursglove BM, Walsh WL (1954) J Am Chem Soc 76:754

    CAS  Google Scholar 

  126. Ogata Y, Ishiguro J (1950) J Am Chem Soc 72:4302

    CAS  Google Scholar 

  127. Gore RC, Hannah RW, Pattacini SC, Porro TJ (1971) Journal of the AOAC 54:1040–1082

    CAS  Google Scholar 

  128. Archer TE, Stokes JD (1983) J Agric Food Chem 31:268–288

    Google Scholar 

  129. Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London

    Google Scholar 

  130. Karlsson MO, Dahlstrom B, Neil A (1988) Characterization of high-affinity binding sites for the antitussive [3H]noscapine in guinea pig brain tissue. Eur J Pharmacol 145:195–203

    PubMed  CAS  Google Scholar 

  131. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  132. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  133. DHU, Karlsruhe (1994) S. 214-215

    Google Scholar 

  134. Voisin H (1969) Materia medic ades hom. Praktikers, Haug Verlag Heidelberg: S. 872

    Google Scholar 

  135. Keller K, Greiner S, Stockebrand P (1990) Hom. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  136. Keller K, Greiner S, Stockebrand P (1990) Hom. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  137. DHU, Karlsruhe (1994) S. 216-217

    Google Scholar 

  138. Voisin H (1969) Materia medica des hom. Praktikers; Haug-Verlag Heidelberg: S. 879–884

    Google Scholar 

  139. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  140. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  141. Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wis-senschaftl. Autorenverlag Leer/Ostfriesland: S. 357-358

    Google Scholar 

  142. Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag, Heidelberg: S. 884

    Google Scholar 

  143. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  144. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2

    Google Scholar 

  145. Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wis-senschaftl. Autorenverlag Leer/Ostfriesland: S. 358-359

    Google Scholar 

  146. DHU, Karlsruhe (1994) S. 218-219

    Google Scholar 

  147. Voisin H, Materia medica des hom. Praktikers, Haug Verlag: S. 885-887

    Google Scholar 

  148. Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  149. Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  150. Voisin H (1969) Materia medica des hom. Praktikters Haug-Verlag, Heidelberg: S. 888–892

    Google Scholar 

  151. Boericke W (1994) Hom. Mittel und ihre Wirkungen, Wis-senschaftl. Autorenverlag Leer/Ostfriesland: S. 360-361

    Google Scholar 

  152. Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  153. Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  154. Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag Heidelbergr S. 245–250

    Google Scholar 

  155. Boericke W (1994) Horn. Mittel und ihre Wirkungen; Wissenschaftl. Autorenverlag Leer/Ostfriesland: S. 99

    Google Scholar 

  156. Keller K, Greiner S, Stockebrand P (1995) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  157. Keller K, Greiner S, Stockebrand P (1995) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  158. Brockhaus R, Essigsäure. In: Ull Bd. 11, S.68

    Google Scholar 

  159. Mar 29, S. 1025

    Google Scholar 

  160. Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf

    Google Scholar 

  161. Banie S (1981) Cancer Lett 11:239

    Google Scholar 

  162. Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M-A, Ito N (1983) Cancer Res 43:4454

    PubMed  CAS  Google Scholar 

  163. Fukushima S, Shibata M, Shiran T, Tamano S, Ito N (1986) Cancer Res 46:1623

    PubMed  CAS  Google Scholar 

  164. Cohen SM, Ellwein LB, Okamura T, Masui T, Johansson SL, Smith RA, Wehner JM, Khachab M, Chappel CI, Shoenig GP (1991) Cancer Res 51:1766

    PubMed  CAS  Google Scholar 

  165. Buettner GR (1993) Arch Biochem Biophys 300:535

    PubMed  CAS  Google Scholar 

  166. Filehne W (1901) Cloetta’s Lehrbuch der Arzneimittellehre und Arzneiverordnungslehre, Verlag von JCB Morh, Tübingen Leipzig, S. 128

    Google Scholar 

  167. Eichholtz F (1942) Lehrbuch der Pharmakologie, Springer-Verlag, Berlin, S. 379

    Google Scholar 

  168. Naeije N, Bracamonte M, Michael O (1983) Crossdesensi-tisation between aspirin and benzoate in asthma, Lancet ii: 1035–1036

    Google Scholar 

  169. Mar 29, S. 1618

    Google Scholar 

  170. Braune G, Schneider H Natriumcarbonat und Natriumhy-drogencarbonat. In: Ull Bd. 17, S. 159 ff

    Google Scholar 

  171. Mar 29, S. 1614

    Google Scholar 

  172. Gmelin’s Handbuch der Anorganischen Chemie (1964) Natrium, System-Nr.: 21, Erg. Bd. 1, 8. Aufl., Verlag Chemie, Weinheim, S. 309

    Google Scholar 

  173. Braune G, Schneider H Natriumcarbonat und Natriumhy-drogencarbonat. In: Ull Bd. 17, S. 159 ff

    Google Scholar 

  174. Hollemann AF, Wiberg E, Lehrbuch der anorganischen Chemie, Walter de Gruyter Verlag, Berlin, S.427ff

    Google Scholar 

  175. Remy H; Lehrbuch der anorganischen Chemie, 9. Aufl., Bd. 1, Akademische Verlagsgesellschaft, Leipzig, S.232

    Google Scholar 

  176. Scanion EF, Milland FP, Hellman L (1990) J Surg Oncol 44(1):47–51

    Google Scholar 

  177. Widmer LK, Hurlimann F, Duchosal F (1967) Anfiologica 4(3-4):193–202

    CAS  Google Scholar 

  178. Mar 31, S. 1467

    Google Scholar 

  179. Danon D, Marikovsky Y, Gasko O (1966) 51-Chromium uptake as a function of red cell age. J Lab Clin Med 67:70–77

    PubMed  CAS  Google Scholar 

  180. Langard S, Norseth T. In: L. Friberg, G.R Nordberg, V.B. Vouk (editors) Handbook on the toxicology of metals. El-sevier Amsterdam. 383

    Google Scholar 

  181. Roche M, Perez-Gimenez E, Layrisse M, Diprisco E (1957) Study of urinary and fecal excretion of radioactive Cr-51 in man. J Clin Invest 36:1181–1192

    Google Scholar 

  182. Heimpel H, Keiderling W, Schoeppe W, Reichhold H, Hoffmann G (1961) Untersuchungen zur Bestimmung der Erythrozytenüberlebenszeit und des Abbauortes der Erythrozyten bei Gesunden mit Hilfe der Cr-51-Markierung in vitro und in vivo. Nucl med 2:217–233

    Google Scholar 

  183. Adam W (1981) Die Bestimmung der Erythrozytenle-benszeit und des Erythrozytenabbauortes. Der Nuklearmediziner 42:161–168

    Google Scholar 

  184. Najean Y (1981) Die Bestimmung des Blutvolumens und ihre praktische Bedeutung in der klinischen Hämatologie. Der Nuklearmediziner 42:115–122

    Google Scholar 

  185. Pachter KGR, Matlok F, Gremiich HU (1988) Merck FT-IR-Atlas, VCH Verlagsgesellschaft, Weinheim, S. 884

    Google Scholar 

  186. Datenblatt zu IR 3.295/83, E. Merck, Darmstadt/ Schu-chardt&Co

    Google Scholar 

  187. Ganguly SC: J Indian Chem Soc 15 (1938) 611; Chem Zbl 1939 I, 4.816

    Google Scholar 

  188. Sträub FB (1935) 42 Hoppe-Seyler’s Z physiol Chem 236

    Google Scholar 

  189. Arbeitsanleitung zum UV-Test L-Äpfelsäure, Test-Combination Nr. 139068 Boehringer Mannheim (1989)

    Google Scholar 

  190. Schweckendiek W (1984) Die Psoriasis vulgaris, eine stoffwechselbedingte Hautkrankheit, Erfahrungsheilkunde 33, 850–858

    CAS  Google Scholar 

  191. Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study, Brit J Dermatol 138, 456–460

    CAS  Google Scholar 

  192. Niboer C, De Hoop D, Langendijk PNJ, Van Loenen AC, Gubbels J (1990) Fumaric acid therapy in psoriasis: a double blind comparison between fumaric acid compound therapy and monotherapy with dimethyl-fumaric acid ester, Dermatologica 81, 33–37

    Google Scholar 

  193. Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R (1987) Perorale Langzeitbehandlung der Psoriasis mit Fumarsäu-rederivaten, Hautarzt 38, 279–285

    PubMed  CAS  Google Scholar 

  194. Raab W (1984) Psoriasis-Behandlung mit Fumarsäure und Fumarsäureestern, Z Hautkr 59, 671–679

    PubMed  CAS  Google Scholar 

  195. Rudenko MI, Andriushkin VN, Artemov VG (1994) The use of mafusol in acute blood loss, Voen Med Zh 33-34

    Google Scholar 

  196. Lure GO, Osipov VP, Charnaia MA (1990) The use of new soviet crystalloid mafusol as a hemodiluent in surgery using artificial circulation, Anesteziol Reanimatol 20-22

    Google Scholar 

  197. Selivanov EA, Khanevich MD, Starokon PM, Slepneva LV, Zybina NN (1992) Activation of the processes of the lipid peroxidation in the small intestinal mucosa and liver in peritonitis and possible ways of their correction by a complex infusion-detoxification therapy, Gematol Transfuziol 37, 13–16

    PubMed  CAS  Google Scholar 

  198. Walker CB, Niebloom TA, Socransky SS (1979) Agar medium for use in succeptibility testing of bacteria from human periodontal pockets, Antimicrob Agents Chemother 16, 452–457

    PubMed  CAS  Google Scholar 

  199. Bernhard T, Gottschalk G (1978) Cell yields of Escheri-chia coli during anaerobic growth on fumarate and molecular hydrogen, Arch Microbiol 116, 235–238

    PubMed  CAS  Google Scholar 

  200. Lauter WM, Brucar MO; USP 2,543,976; zit. nach CA 489 le

    Google Scholar 

  201. Scott KN (1972) J Am Chem Soc 94:8564–8568

    PubMed  CAS  Google Scholar 

  202. Ebel S (1977) Handbuch der Arzneimittelanalytik, Verlag Chemie, Weinheim, New York, S. 111

    Google Scholar 

  203. Elks J, Ganellin CR (Hrsg.) (1990) Dictionary of Drugs, 1. Aufl., Chapman and Hall, London New York Tokyo Melbourne Madras, S. 413

    Google Scholar 

  204. Mar 31, S. 1753

    Google Scholar 

  205. Sewester CS, Olin BR, Hebel SK, Connell SI, Dombek CE, Kastrup EK (1990) Drug facts and comparisons, Lip-pincott Company, St. Louis, Missouri:S. 133–136

    Google Scholar 

  206. Kurz H (1986) Elektrolyte und Infusionslösungen, In: Ammon HPT (Hrsg.) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, S. 547–556

    Google Scholar 

  207. Ruoff HJ (1986) Antazida, In: Ammon HPT (Hrsg.) Arz-neimittel-Neben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart: S594–599

    Google Scholar 

  208. Methoden der enzymatischen Lebensmittelanalytik (1975/19) Lebensmittelanalytik, Boehringer, Mannheim

    Google Scholar 

  209. Sporns P (1982) J Assoc Off Anal Chem 65(3):567–571, zit. nach CA (1982) 97:4757c

    PubMed  CAS  Google Scholar 

  210. Rhys Williams AT, Winfield SA (1982) Analyst (London) 107(1978):1092–1094, zit. nach CA (1982) 97:214366a

    CAS  Google Scholar 

  211. Gal S, Schilling P (1972) Z Lebensm Unters Forsch 148(1):18–22, zit. nach CA 76:98061n

    CAS  Google Scholar 

  212. Nakanishi H (1983) J Assoc Off Anal Chem 66(6):1528–1531, zit. nach CA (1984) 100:21629k

    PubMed  CAS  Google Scholar 

  213. Curry KK, Evans JW, Schwab G (1983) HRC CC J, High Resolut Chromatogr Commun 6(9):510–511; zit. nach CA 99:224450d

    CAS  Google Scholar 

  214. Merck (1992/1993) Katalog Reagenzien, Diagnostica, Chemikalien

    Google Scholar 

  215. Hochgeschwender K, Zimgiebl E, Natriumhydroxid. In: Ull Bd. 17, S. 210 ff

    Google Scholar 

  216. Mar 29, S. 1617

    Google Scholar 

  217. Schreiner S (1982) Schwefel-Sauerstoff-Säuren, Kap. 5. 1-Hydroxyalkansulfite. In: Ullmanns Encyklopädie der technischen Chemie, Verlag Chemie, Weinheim, 4. Aufl., Bd. 21, S. 112; s. auch Süss HU (1985) Bleaching. In: llmann’s Encyclopedia of industrial chemistry, 5. Aufl., Vol. A4, S. 196

    Google Scholar 

  218. Beilstein 1, a) 577, b) I 302, c) II 642, d) III 2583, e) IV 3052

    Google Scholar 

  219. Gmelins Handbuch der Anorganischen Chemie (1964) Verlag Chemie Weinheim, 8. Aufl., Na, 21, a) Erg. Bd. 1, S. 256-257

    Google Scholar 

  220. Gmelins Handbuch der Anorganischen Chemie (1966) Verlag Chemie Weinheim, 8. Aufl., Na, 21, b) Erg. Bd. 3, S. 1071-1073

    Google Scholar 

  221. Sachs AP (1938) US Pat 2,135,474

    Google Scholar 

  222. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM (1993) First experience in healthy volunteers with techneticum-99m-L,L-ethylendicysteine, a new renal imaging agent, Eur J Nucl Med 20:738–746

    PubMed  Google Scholar 

  223. Maini CL, Antonacci P, Sargiotto A, Castellano G, Podio V (1989) Dynamic renal scanning using 99mTc-MAG-3 in man, Eur J Nucl Med 15:635–640

    PubMed  CAS  Google Scholar 

  224. Blaufox MD (1972) Evaluation of renal function and disease with radionuclides In: Potchen ED, McCready VR (Eds.). Progress in Nuclear Medicine. Basel

    Google Scholar 

  225. Dumont M, Marchand L, Laroche B, Robert G, Thabet M (1990) Scintigraphic evaluation of renal function after extracorporeal shock-wave lithotripsy. Can Assoc Radiol J 41:138–140

    PubMed  CAS  Google Scholar 

  226. Sfakianakis GN, Bourgoignie JJ, Jaffe D, Kyriakides G, Perez-Stable E, Duncan RC (1987) Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. J Nucl Med 28:1383–1392

    PubMed  CAS  Google Scholar 

  227. Grant ME, Herron KG, MacDougall ML, Preston DF, Moore WV, Wiegmann TB (1991) Single-dose subcutaneous iodine-131-iodohippurate for determination of renal plasma flow. J Nucl Med 32:1452–1454

    PubMed  CAS  Google Scholar 

  228. Russell CD, Dubovsky EV, Scott JW (1989) Estimation of ERPF in adults from plasma clearance of 131 I-hippuran using a single injection and one or two blood samples. Int J Rad Appl Instrum B 16:381–383

    PubMed  CAS  Google Scholar 

  229. Lear JL, Feyerabend A, Gregory C (1989) Two-compartment, two-sample technique for accurate estimation of effective renal plasma flow: theoretical development and comparison with other methods. Radiology 172:431–436

    PubMed  CAS  Google Scholar 

  230. Le Cloirec J, Devillers A, Rivallan J (1994) Les explorations isotopiques dans la surveillance du transplant renal. J Radiol 75:15–17

    PubMed  Google Scholar 

  231. ICRP (1987) Annals of the ICRP. Band 18; ICRP Publ. Nr. 53

    Google Scholar 

  232. Bhargava KK, Acharya SA (1989) Labeling of monoclonal antibodies with radionuclides. Semin Nucl Med 19:187–201

    PubMed  CAS  Google Scholar 

  233. B Anz (1990) 143:3951

    Google Scholar 

  234. Husakova M, Laznicek M, Kvetina J (1989) Cesk Farm 38(1):26–28

    PubMed  CAS  Google Scholar 

  235. Kulkarni PV, Corbett JR (1990) Semin Nucl Med 20(2):119–129

    PubMed  CAS  Google Scholar 

  236. Poser D (1977) Jahresbericht des Vereins für Kernverfahrenstechnik und Analytik, Dresden, S. 71-72

    Google Scholar 

  237. Buttermann G (1987) Ergebnisse der Radioiodtherapie benigner Schilddrüsenerkrankungen. In: Radioiodtherapie bei Schilddrüsenerkrankungen. G. Buttermann (Hrsg:). pmi-Verlag Frankfurt:55–73

    Google Scholar 

  238. Börner W, Eichner R, Reiners C, Ruppert G, Schaffhauser R, Seybold K (1978) Zur Diagnostik und Therapie des Schilddrüsenmalignoms. Therapiewoche 28:9272

    Google Scholar 

  239. Schlegel G, Wendt T (1981) Differenzierte Therapie des Schilddrüsenkarzinoms. Diagnostische Aspekte in der Nachsorge. Tumor Diagnostik 3:122

    Google Scholar 

  240. Moser E, Fritsch S, Kreisig T (1987) Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms: Nuklearmedizinische Aspekte. In: Radioiodtherapie bei Schilddrüsenerkrankungen. G. Buttermann (Hrsg.) pmi-Verlag Frankfurt:79–94

    Google Scholar 

  241. Bell E (1979) Therapie der Hyperthyreose mit I 131 bei diffuser Struma. Der Nuklearmediziner 4:214

    Google Scholar 

  242. Buttermann G (1987) Heutiger Stellenwert der Radiotherapie in der Behandlung der thyreoidalen Autonomie — Indikationen, Alternativen, Ergebnisse. In: Radiotherapie bei Schilddrüsenerkrankungen. G. Buttermann (Hrsg.). pmi-Verlag Frankfurt:37–54

    Google Scholar 

  243. Dobyns MB et al. (1974) Malignant and benign neoplasms of the thyroid in PTS treated for hyperthyroidism: A report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol 38:976

    CAS  Google Scholar 

  244. Edmonds CJ, Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Brit J Radiol 59:45

    PubMed  CAS  Google Scholar 

  245. Van Nostrand D, Neutze J, Atkins F (1986) Side effects of rational dose iodine 131-therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:10

    Google Scholar 

  246. Shaw SM (1985) Drugs and diseases that may alter the biodistribution or pharmacokinetics of radiopharmaceuticals. Pharmacy International, December 1985:293

    Google Scholar 

  247. Brin (1953) Biochem Prepar 3:61

    Google Scholar 

  248. Richterich R, Colombo JP (1978) Klinische Chemie, 4. Aufl., S. Karger, München

    Google Scholar 

  249. Boehringer Test-Kombination L-Milchsäure (L-Lactat) Nr. 139084

    Google Scholar 

  250. Cassanas G, Morssli M, Fabregue E, Bardet L (1991) J Raman Spectroscopy 22:409–413

    CAS  Google Scholar 

  251. Heinerth E, Silicate. In: Ull Bd. 21, S. 412 ff

    Google Scholar 

  252. Hag Bd. II, S. 1034

    Google Scholar 

  253. Gmelin’s Handbuch der Anorganischen Chemie (1935) Molybdän, System-Nr. 53, 8. Aufl., Verlag Chemie, Weinheim, S. 214 ff

    Google Scholar 

  254. Sebenik RF, Dorfler RR, Laferty JM (1990) Molybdenum and Molybdenum Compounds. In: Elvers B, Hawkins S; Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A16, VCH Verlagsgesellschaft, Weinheim, S. 663

    Google Scholar 

  255. Mitchell PCH (1990) ibd., S. 675

    Google Scholar 

  256. Gmelin’s Handbuch der Anorganischen Chemie (1935) Molybdän, System-Nr. 53, 8. Aufl., Verlag Chemie, Weinheim, S.214 ff

    Google Scholar 

  257. Mitchell PCH (1990) Molybdenum and Molybdenum Compounds. In: Elvers B, Hawkins S; Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A16, VCH Verlagsgesellschaft, Weinheim, S. 675

    Google Scholar 

  258. Karklins P, Pelcmane I, Ramina L (1984) Latv PSR Zinat Akad Vestis 10:108–112, zit. nach CA 102(5):4434w

    Google Scholar 

  259. Baniel AM, Eyal AM (1991) Eur Pat Appl EP 432.610, EP 90-123.108, zit. nach CA 115(15): 157,166z

    Google Scholar 

  260. Laue W, Thiemann M, Scheibler E, Wiegand KW (1991) Nitrates and Nitrites. In: Elvers B, Hawkins S, Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A17, VCH Verlagsgesellschaft, Weinheim, S. 266 ff

    Google Scholar 

  261. Korn Bd. 1, S. 105

    Google Scholar 

  262. Mar 29, S. 1617

    Google Scholar 

  263. Brandt W, Catholy G, Buennig R, Wittstock D (1986) Ger. (East) DD 237, 310; zit. nach CA (1987) 107:6774e

    Google Scholar 

  264. Brandt W, Bruennig R, Catholy G, Wittstock D (1986) Ger. (East) DD 237,308; zit. nach CA (1987) 107:39210w

    Google Scholar 

  265. Nelson, Cretcher (1930) Am Soc 52:3703

    Google Scholar 

  266. FIDES Laboratorio M, Cuatrecases (1965) Span 302,338 zit. nach CA (1966) 65:15169e

    Google Scholar 

  267. Arendaruk AP, Serebryakov LA, Skoldinov AP (1963) Med Prom SSSR 17(6):6–8; zit. nach CA (1963) 33:11234d

    PubMed  CAS  Google Scholar 

  268. Morssli M, Cassanas G, Bardet L, Pauvert B, Terol A (1991) Spectrochim Acta, Part A 47A(5):529–541; zit. nach CA (1991) 115:81100a

    CAS  Google Scholar 

  269. Simkovic I, Alfoldi J, Matulova M (1986) Carbohydr Res 152:137–141

    CAS  Google Scholar 

  270. Migonney V, Lacroix MD, Ratner BD, Jozefowicz M (1995) J Biomater Sci Polym Ed 7(3):265–275; zit. nach CA 123:40894j

    PubMed  CAS  Google Scholar 

  271. Kimura Y, Yamane H, Komatsuzaki S (1994) Jpn Kokai Tokkyo Kohe JP 06,336,523; zit. nach CA (1995) 122:274142u

    Google Scholar 

  272. Hansson A (1961) Acta Chem Scand 15:934

    CAS  Google Scholar 

  273. Bertsch-Frank B (1991) Peroxo Compounds, Inorganic. In: Elvers B, Hawkins S; Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A19, VCH Verlagsgesellschaft, Weinheim, S. 182 ff

    Google Scholar 

  274. Mar 29, S. 1618

    Google Scholar 

  275. Gallone P (1986) Chlorine Oxides and Chlorine Oxygen Acids. In: Gerhartz W (Hrsg.) Ullmanns’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A6, VCH Verlagsgesellschaft, Weinheim, S.515 f

    Google Scholar 

  276. Gemlin’s Handbuch der Anorganischen Chemie (1970) Natrium, System-Nr.: 21, Erg. Bd. 5, 8. Aufl., Verlag Chemie, Weinheim, S. 1781

    Google Scholar 

  277. Aanderud S, Sundsfjord J, Aarbakke J (1984) Amiodaron inhibits conversions of T4 to T3 in isolated rat hepatocytes. Endocrinol 115:1605–1608

    CAS  Google Scholar 

  278. Anbar M, Guttmann S, Lewitus Z (1959) The mode of action of perchlorate ions on the iodine uptake of the thyroid gland. Int J Appl Radiat 7:87–89

    PubMed  CAS  Google Scholar 

  279. Bartalena L, Brogioni S, Grasso L, et al. (1996) Treatment of amiodarone-induced thyreotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab 81:2930–2933

    PubMed  CAS  Google Scholar 

  280. Broekhuysen J, Laruel R (1969) Research on the benzofuran series XXXVIII: Comparative study of transit and metabolism of amiodarone in different species of animals and humans. Arch Int Pharmacodyn 177:340–359

    PubMed  CAS  Google Scholar 

  281. Eichler O, Hackenthal E (1962) Über Ausscheidung und Stoffwechsel von Perchlorate gemessen mit 36 C104. Naunyn-Schm Arch Exp Pathol Pharmakol 243:554–565

    CAS  Google Scholar 

  282. Goldman SJ, Stanbury JB (1973) The metabolism of perchlorate in the rat. Endocrinol 92:1536–1538

    CAS  Google Scholar 

  283. Martino E, Aghini-Lombardi F, Mariotti S, et al. (1986) Treatment of amiodarone-induced thyreotoxicosis by simultaneous administration of potassium perchlorate and methimazole J Endocrinol Invest 9:201–207

    CAS  Google Scholar 

  284. Martino E, Aghini-Lombardi F, Mariotti S, et al. (1987) Amiodarone: a common source of iodine-induced thyreotoxicosis. Horm Res 26:158–171

    PubMed  CAS  Google Scholar 

  285. Mazonson PD, Williams ML, Cantley MK, et al. (1984) Myxedema coma during long-term amiodarone therapy. Am JMed 77:751–754

    CAS  Google Scholar 

  286. Postel S (1957) Placental transfer of perchlorate and triiodo-thyronine in the guinea pig. Endocrinol 60:53–66

    CAS  Google Scholar 

  287. Smyrk TC, Goellner JR, Brennan MD, et al. (1987) Pathology of the thyroid in amiodarone-associated thyreotoxicosis. Am J Surg Path 11:197–204

    PubMed  CAS  Google Scholar 

  288. Trotter WR (1962) The relative toxicity of antithyroid drugs. J New Drugs 2:333–343

    PubMed  CAS  Google Scholar 

  289. Wolff J (1998) Perchlorate and the thyroid gland. Pharmacol Rev 50:89–105

    PubMed  CAS  Google Scholar 

  290. Wolff J, Maury JR (1963) Thyroidal iodide transport: The role of ion size. Biochim Biophys Acta 69:58–67

    PubMed  CAS  Google Scholar 

  291. Wyngaarden JB, Wright BM, Ways P (1952) The effect of certain anions upon the accumulation and retention of iodide by the thyroid gland. Endocrinol 50:537–549

    CAS  Google Scholar 

  292. Reich E, Bogl KW (1989) Nuklearmedizin 28(5):201–207

    PubMed  CAS  Google Scholar 

  293. Mar 31, S. 1467

    Google Scholar 

  294. Intenzo CM, Park CH, Cohen SN (1990) Clin Nucl Med 15(5)313–314

    PubMed  CAS  Google Scholar 

  295. Beierwaltes WH (1990) J Nucl Med 31(4):400–402

    PubMed  CAS  Google Scholar 

  296. Berke RA, Johnson RM, Henegar GC (1967) Am J Roentgenol Radium Ther Nucl Med 100(4):844–846

    PubMed  CAS  Google Scholar 

  297. Atkins HL, Thomas SR, Buddemeyer U, Chervu LR (1990) J Nucl Med 31(3):378–380

    PubMed  CAS  Google Scholar 

  298. Mar 31, S. 1467

    Google Scholar 

  299. Glaubitt D (1979) 32P-Behandlung der Polycythaemia rubra vera. Der Nuklearmediziner 4, 2:255–267

    Google Scholar 

  300. Pfannenstiel H (1979) Endolymphatische Behandlung mit P-32-I-131. Der Nuklearmediziner 4, 2:300–313

    Google Scholar 

  301. Sikov MR et al. (1958) Anomalous Development Induced in the Emryonic Rat by the Maternal Administration of Radiophosphorus. Am J Anat. 103:137–162

    PubMed  CAS  Google Scholar 

  302. Keeling DH, Sampson CB (1984) Adverse Reactions to Radiopharmaceuticals. United Kingdom 1977–1983. Br J Radiol. 57:1091–1096

    PubMed  CAS  Google Scholar 

  303. Rhodes BA et al. (1980) Adverse Reactions Radiopharmaceuticals. J Nucl Med 21, 11:1107

    PubMed  CAS  Google Scholar 

  304. Montz R (1978) Therapie mit 32Phosphor. In: L. Diethelm, F. Heuck, O. Olsson, F. Strnad, H. Vieten, A. Zuppinger (Hrsg) Nuklearmedizin, Teil 2. Diagnostik, Therapie, Klinische Forschung. Springer, Berlin, Heidelberg, New York (Handbuch der medizinischen Radiologie)

    Google Scholar 

  305. Lawrence JH (1940) Nuclear Physics and Therapy: Preliminary Report on a New Method for the Treatment of Leukemia and Polycythemia. Radiology 35:51–60

    CAS  Google Scholar 

  306. Haas H, Phosphoroxide, Phosphorsäuren und Phosphate. In: Ull Bd. 18, S. 320 ff

    Google Scholar 

  307. Komm DAB 7-DDR (1964) Akademie-Verlag, Berlin

    Google Scholar 

  308. Pouchert CJ (1985) The Aldrich Library of FT-IR-Spectra, 1.Aufl.

    Google Scholar 

  309. Kommentar Europäisches Arzneibuch, 7. Aufl., Bd. III, Govi-Verlag 1982, S. 613-616

    Google Scholar 

  310. Hansen PE, Thiessen H, Brodersen R (1979) Acta Chem Scand B 33:281–293

    PubMed  CAS  Google Scholar 

  311. Pachaly P (1983) Dünnschichtchromatographie in der Apotheke, Wissenschaftliche Verlagsgesellschaft mbH, 2. Aufl., Stuttgart, S. 160

    Google Scholar 

  312. Eppert G, Liebscher G, Ihrke M, Arendt G (1985) J Chromatogr 350:471–476

    CAS  Google Scholar 

  313. Schleuder M, Beyrich T (1974) Pharmazie 29:448–452

    PubMed  CAS  Google Scholar 

  314. Eger K, Aengstenheyster G, Gegenbach R (1978) Dtsch Apoth Ztg 118:1047–1048

    Google Scholar 

  315. Kim M, Stewart, JT (1990) J Liquid Chromatogr 13:213–237; zit. nach CA 113:29381n

    CAS  Google Scholar 

  316. Carlson M, Thompson RD (1987) J Liquid Chromatogr 10:997–1009; zit. nach CA 107:84008x

    CAS  Google Scholar 

  317. Europäisches Arzneibuch, 2. Ausgabe

    Google Scholar 

  318. Registry of Toxic Effects of Chemical Substances (RTECS): V05075000

    Google Scholar 

  319. Pharmeuropa (1996) 8(1):79-81

    Google Scholar 

  320. McGreevy PB, Marsden PD (1986) Protozoan infections of man, american trypanosomiasis and leishmaniasis. In: Chemotherapy of parasitic diseases, edited by Campbell WC and Rew RS. Plenum Press: New York and London 1986:115–127

    Google Scholar 

  321. WHO (1982) Report of the informal meeting of the chemotherapy of visceral leishmaniasis, WHO Offset Publ. TDR/Chemleish/VL 82.3:19 pp

    Google Scholar 

  322. Chulay JD, Bhatt SM, Muigai R, Ho M, Gachihi G, Were JBO, Chunge C, Bryceson ADM (1983) A comparison of three dosage regimens of sodium stibigluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis 148:148–155

    PubMed  CAS  Google Scholar 

  323. Rees PH, Keating MI, Kager PA, Hochmeyer WT (1980) Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2:226–229

    PubMed  CAS  Google Scholar 

  324. WHO (1983) Report on the workshop on chemotherapy of old world cutaneous leishmaniasis, WHO Offset Publ. TDR/Leish/CL-JER/ 83.3:19 pp

    Google Scholar 

  325. Thakur CP (1984) Epidemiological, clinical and therapeutic feature of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 78:391–398

    PubMed  CAS  Google Scholar 

  326. Bryceson ADM (1970) Diffuse cutaneous leishmaniasis in Ethiopia: II. Treatment Trans R Soc Trop Med Hyg 64:369–379

    CAS  Google Scholar 

  327. Chulay JD, Oster CN, McGreevy PB, Kreutzer RD, Hendricks LD (1988) American cutaneous leishmaniasis: Clinical presentation and problems of patient managment. Rev Soc Bras Med Trop 21:165–172

    PubMed  CAS  Google Scholar 

  328. Oster CN, Chulay JD, Hendricks LD, Pamplin CL, Ballou WR, Berman JD, Takafuji ET, Tramont EC, Canfield CJ (1985) American cutaneous leishmaniasis: A comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 34:856–860

    PubMed  CAS  Google Scholar 

  329. Rocha RAA, Sampaio RN, Guerra M, Magalhaes A, Cuba CC, Barreto AC, Marsden PD (1980) Apparent glucantime failure in five patients with mucocutaneous leishmaniasis. J Trop Med Hyg 83:131–139

    PubMed  CAS  Google Scholar 

  330. Sampaio RNR (1984) Tratamento hospitalar de leishmaniose cutaneo-mucosa. Masters thesis, Universidade Federal de Belo Horizonte.

    Google Scholar 

  331. Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPT, Costa JLM Llanos-Cuentas EA (1985) High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. Am J Trop Med Hyg 34:710–713

    PubMed  CAS  Google Scholar 

  332. Gagliardi ART, Veiga JPR, Rosa TT, Marsden PD (1985) Pentavalent antimony inhibiton of water transport by the toad bladder. Bras J Med e Biol Res

    Google Scholar 

  333. Sampaio RNR, Rocha RAA, Marsden PD, Cuba CC, Barreto AC (1980) Leishmaniose tegumentar americana: Casuistica do Hospital escola da UnB Ann Brasil Dermatol 55:69–76

    Google Scholar 

  334. Teworte W, Natriumsulfat und Natriumhydrogensulfat. In: Ull, Bd. 17, S.211 ff

    Google Scholar 

  335. Gmelin’s Handbuch der Anorganischen Chemie (1928) Natrium, System-Nr. 21, 8. Aufl., Verlag Chemie Weinheim, Belin, S. 560

    Google Scholar 

  336. Hag. Bd. Vla, S.140f

    Google Scholar 

  337. Merck-Katalog Reagenzien, Diagnostica, Chemikalien 1992/93

    Google Scholar 

  338. Gmelin’s Handbuch der Anorganischen Chemie (1928) Natrium, System-Nr. 21, 8. Aufl., Verlag Chemie, Weinheim, S. 520

    Google Scholar 

  339. Pistor H, Knippschild G, Meffert A, Rasch J, Bor-Verbi düngen, anorganische. In: Ull Bd. 8, S. 663 ff

    Google Scholar 

  340. Smith RA (1985) Boric Oxides, Boric Acid and Borati In: Gerhartz W (Hrsg.) Ullmann’s Encyclopedia of Indu rial Chemistry, 5. Aufl., Bd. A4, VCH Verlagsgesellscha Weinheim, S. 273

    Google Scholar 

  341. Mar 29, S. 1548

    Google Scholar 

  342. Smith RA (1985) Boric Oxides, Boric Acid and Borates. In: Gerhartz W (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A4, VCH Verlagsgesellschaft, Weinheim, S. 270 ff

    Google Scholar 

  343. Pistor H, Knippschild G, Meffert A, Rasch J, Bor-Verbindungen, anorganische. In: Ull Bd. 8, S. 663 ff

    Google Scholar 

  344. Theis G, Thiocyansäure und anorganische Thiocyanate. In: Ull Bd. 23, S. 163 ff

    Google Scholar 

  345. Hag Bd. II. S. 966, Bd. VIa, S. 133

    Google Scholar 

  346. U.S. pat. 2,895,988 (1959, Sterling Drug) CA 54:1.445

    Google Scholar 

  347. McChesney EW, Banks WF Jr (1974) Urinary excretion of Three Oral Cholecystographic Agents in Man, Proc Soc Exp Biol Med 119:1027–1030

    Google Scholar 

  348. Berk RN, Loeb PM, Cobo Frenkel A, Barnhart JL (1977) The biliary and urinary excretion of sodium tyropanoate and sodium ipodate in dogs: pharmacokinetics, influence of bile salts and choleretic effects with comparison to iopanoic acid. Invest Radiol 12:85–95

    PubMed  CAS  Google Scholar 

  349. Cooke WJ, Cooke LM (1983) Biliary and urinary excretion of tyropanoic acid and its metabolites in the dog. Invest Radiol 18:285–292

    PubMed  CAS  Google Scholar 

  350. McChesney EW, Banks WF Jr (1974) Urinary excretion of Three Oral Cholecystographic Agents in Man. Proc Soc Exp Biol Med 119:1027–1030

    Google Scholar 

  351. Fischer HW, Burgener FA (1974) Fractionated dose administration schedule for cholecystography. Invest Radiol 9:24–31

    PubMed  CAS  Google Scholar 

  352. Fon GT Hunter TB, Berk RN, Capp MP (1980) The effect of diet and fasting on gallbladder opacification during oral cholecystography in dogs as measured by computed tomography. Radiology 136:585–592

    PubMed  CAS  Google Scholar 

  353. Berk RN, Loeb PM (1976) Pharmacology and physiology of the biliary radiographic contrast materials. Semin Roentgenol 11:147–156

    PubMed  CAS  Google Scholar 

  354. Oliphant M, Whalen JP, Evans JA (1974) Time of optimal gall-bladder opacification with bilopaque (tyropanoate sodium). Radiology 112:531–532

    PubMed  CAS  Google Scholar 

  355. Muhlethaler CA, Gerlock AJ Jr., Amberg JR, Avant GR (1982) Radiographic appearance of the nonabsorbed (unconjugated) and conjugated sodium tyropanoate (Bilopaque) in the bowel. Invest Radiol 17:506–509

    Google Scholar 

  356. Muhlethaler CA, Gerlock AJ Jr., Avant GR (1981) Conjugated sodium tyropanoate (Bilopaque) in the bowel: significance of its presence or absence after first dose oral cholecystography. Radiology 141:311–316

    Google Scholar 

  357. Thoeni RF, Moss AA (1982) A clinical trial of oral cholecystography using combinations of contrast agents and two consecutive doses. Radiology 144:271–275

    PubMed  CAS  Google Scholar 

  358. Felicetta JV, Green WL, Nelp WB (1980) Inhibition of hepatic binding of thyroxine by cholecystographic agents. J Clin Invest 65:1032–1040

    PubMed  CAS  Google Scholar 

  359. Felicetta JV, Czanko R, Huber-Smith MJ, McCann DS (1986) Cholecystographic agents and sulfobromophthalein inhibit the binding of L-thyroxine to plasma membranes of rat hepatocytes. Endocrinology 118:2500–2504

    PubMed  CAS  Google Scholar 

  360. Felicetta JV, Green WL, Huber-Smith MJ (1983) Effects of cholecystographic agents and sulfobromophthalein on binding of thyroid hormones to serum proteins. J Clin Endocrinol Metab 57:207–212

    PubMed  CAS  Google Scholar 

  361. Noguchi K, Suzuki H, Nakahata M, Kurosawa S, Nakagawa S (1986) Prolonged treatment of hyperthyroidism with sodium tyropanoate, an oral cholecystographic agent: a re-evaluation of its clinical utility. Clin Endocrinol (Oxf) 25:293–301

    CAS  Google Scholar 

  362. Hoppe JO, Ackerman JH, Larsen AA, Moss J (1970) Sodium tyropanoate. A new oral cholecystographic agent. J Med Chem 13:997–999

    PubMed  CAS  Google Scholar 

  363. Van Lommen GRE, De Bruyn MFL, Schroven MFJ (Jansen Pharm.N.V.) AU 8436326, EP 145067, JP 85132977, US 4654362, zit. nach (1989) Drug Fut 14:957-959

    Google Scholar 

  364. Van Lommen GRE, De Bruyn MFL, Schroven MFJ (1990) J Pharm Belg 45:355–360

    PubMed  Google Scholar 

  365. Janssens WJ (1992) Pharmacology of nebivolol. J Pharm Belg 47:323–327

    PubMed  CAS  Google Scholar 

  366. Stoleru L, Wijns W, van Eyll C, Bouvy T, Van Nueten L, Pouleur H (1993) Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol. J Cardiovasc Pharmacol 22:183–190

    PubMed  CAS  Google Scholar 

  367. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM (1995) Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/No-dependent mechnism. J Pharmacol Exp Ther 274:1067–1071

    PubMed  CAS  Google Scholar 

  368. Pauwels PJ, Van Gompel P, Leysen JE (1991) Human beta 1-and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known beta-adrenergic blockers. Biochem Pharmacol 42:1683–1689

    PubMed  CAS  Google Scholar 

  369. Chan TY, Woo KS, Nicholls MG (1992) The application of nebivolol in essential hypertension: a double-blind randomized, placebo-controlled study. Int J Cardiol 35:387–395

    PubMed  CAS  Google Scholar 

  370. Laeourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W (1992) Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 32:660–666

    Google Scholar 

  371. Lacourciere Y, Arnott W (1994) Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 8:283–288

    PubMed  CAS  Google Scholar 

  372. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P (1993) Long-term (3-month) effects of a new beta-blokker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 21:1094–1100

    PubMed  CAS  Google Scholar 

  373. De Cree J, Van Nueten L, Geukens H, Verhaegen H (1992) Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 12:159–163

    PubMed  Google Scholar 

  374. Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM (1993) Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmaco 21:856–862

    Google Scholar 

  375. Drugs Fut (1987) 12(8):758-759

    Google Scholar 

  376. Davis R, Whittington R, Bryson HM (1997) Drugs 53:608–636

    PubMed  CAS  Google Scholar 

  377. Ellingrod VL, Perry PJ (1995) Am J Health-Syst Pharm 52:2799–2812

    PubMed  CAS  Google Scholar 

  378. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Frank DY (1995) J Clin Psychiatry 56(Suppl 6):3–11

    PubMed  Google Scholar 

  379. Greene DS, Barbhaiya RH (1997) Drug Disposition 33:260–275

    CAS  Google Scholar 

  380. Malik K (1996) J Psychopharmacol 10(Suppl 1):1–4

    CAS  Google Scholar 

  381. Eison AS, Eison MS, Torrente JR (1990) Psychopharmacol Bull 26:311–315

    PubMed  CAS  Google Scholar 

  382. Rickeis K, Robinson DS, Schweizer E, Marcus RN, Roberts DL (1995) J Clin Psychiatry 56(Suppl 6):43–46

    Google Scholar 

  383. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN (1996) J Clin Psychiatry 57(Suppl 2):31–38

    PubMed  CAS  Google Scholar 

  384. Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF (1995) J Clin Psychiatry 56(Suppl 6):30–36

    PubMed  Google Scholar 

  385. Preskorn SH (1995) J Clin Psychiatry 56(Suppl 6): 12–21

    PubMed  Google Scholar 

  386. Fawcett J, Marcus RN, Anton SF, O’Brien K, Schwiderski U (1995) J Clin Psychiatry 56(Suppl 6):37–42

    PubMed  Google Scholar 

  387. Olausson P, Ericson M, Petersson A, Kosowski A, Soderpalm B, Engel JA (1998) Alcohol 15:77–86

    PubMed  CAS  Google Scholar 

  388. Armitage R, Yonkers K, Cole D, Rush AJ (1997) J Clin Psychopharmacol 17:161–168

    PubMed  CAS  Google Scholar 

  389. Sharpley AL, Williamson DJ, Attenburrow MEJ, Pearson G, Sargent P, Cowen PJ (1996) Psychopharmacology (Berl) 126:50–54

    CAS  Google Scholar 

  390. Montgomery SA (1996) J Psychopharmacol 10(Suppl 1):5–10

    CAS  Google Scholar 

  391. Dockens RC, Greene DS, Barbhaiya RH (1996) J Clin Pharmacol 36:160–167

    PubMed  CAS  Google Scholar 

  392. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995) J Clin Psychopharmacol 15:399–408

    PubMed  CAS  Google Scholar 

  393. Barbhaiya RH, Shukla UA, Natarajan CS, Behr DA, Greene DS, Sainati SM (1995) Clin Pharmacol Ther 58:390–398

    PubMed  CAS  Google Scholar 

  394. Ferry N, Bernard N, Cuisinaud G, Rougier P, Trepo C, Sassard J (1994) Fundam Clin Pharmacol 8:463–473

    PubMed  CAS  Google Scholar 

  395. Drugs Fut (1987) 12(8):758-759

    Google Scholar 

  396. Kamihara S, Kaneuchi T, Uchiyama K, Terada T, EP 574952, zit. nach CA (1994) 120:298463

    Google Scholar 

  397. Betzing H, Biedermann J, Materne C, Neuser V, DE 2924011, zit. nach CA (1981) 94:156740

    Google Scholar 

  398. Fujimaki Y, Sudo K, Hakusui H (1992) J Chromatogr 575(2):261–268

    PubMed  CAS  Google Scholar 

  399. Fujimaki Y, Sudo K, Tachizawa H (1988) J Chromatogr 433:235–242

    PubMed  CAS  Google Scholar 

  400. Drugs Fut (1989) 14(1):17-18

    Google Scholar 

  401. Fujimaki Y, Hasimoto K, Sudo K (1990) Biotransformation of a new pyrrolidinone cognition-enhancing agent: isolation and identification of metabolites in human urine. Xenobiot 20:1081–1094

    CAS  Google Scholar 

  402. Fujimaki Y, Sudo K, Hakusui H et al. (1992) Single-and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers. J Pharm Pharmacol 44:750–754

    PubMed  CAS  Google Scholar 

  403. Fujimaki Y, Sudo K, Hakusui H (1995) In vitro metabolism of nefiracetam by liver microsomes from rats, dogs and monkeys. Arzneim Forsch 45:748–752

    CAS  Google Scholar 

  404. Fujimaki Y, Sudo K, Hakusui H (1993) Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. Xenobiot 23:61–70

    CAS  Google Scholar 

  405. Harada S, Sakaguchi Y, Shimada M et al. (1995) Male reproductive toxicity study of nefiracetam in rats. J Toxicol Sci 20:309–317

    PubMed  CAS  Google Scholar 

  406. Huang CS, Ma JY, Marszalec W et al. (1996) Effects of the nootropic drug nefiracetam on the GABA A receptorchannel complex in dorsal root ganglion neurons. Neuropharmacol 35:1251–1261

    CAS  Google Scholar 

  407. Joshii M, Watabe S, Sakurai T et al. (1997) Cellular mechanisms underlaying cognition-enhancing actions of nefiracetam (DM-9384). Behav Brain Res 83:185–188

    Google Scholar 

  408. Joshii M, Watabe S (1994) Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells. Brain Res 642:123–131

    Google Scholar 

  409. Nabeshima T, Tohyama K, Kameyama T (1990) Effects of DM-9384, a pyrrolidone derivative, on alcohol-and chlordiazepoxide-induced amnesia in mice. Pharmacol Biochem Behav 36:233–236

    PubMed  CAS  Google Scholar 

  410. Nabeshima T, Tohyama K, Murase K et al. (1991) Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABA A and muscarinic receptors induced by cycloheximide. J Pharmacol Exp Ther 257:271–275

    PubMed  CAS  Google Scholar 

  411. Nishizahki T, Matsuoka T, Nomura T et al. (1998) Nefiracetam modultes acetylcholine receptor currents via two different signal transduction pathways. Mol Pharmacol 53:1–5

    Google Scholar 

  412. Odumeru O, Murphy KJ, O’Connell AW et al. (1997) Influence of nefiracetam on NGF-induced neuritogenesis and neural cell adhesion molecule polysialic acid expression: in vivo and in vitro comparisons. Behav Brain Res 83:173–178

    PubMed  CAS  Google Scholar 

  413. Sakurai T, Kato T, Mori K et al. (1998) Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci Lett 246:69–72

    PubMed  CAS  Google Scholar 

  414. Shimada H, Hattori C, Tanaka N et al. (1994) Mutagenicity study of the new cognition-enhancing agent nefiracetam. Arzneim Forsch 44:251–253

    CAS  Google Scholar 

  415. Watabe S, Yamaguchi H, Ashida S (1993) DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex. Eur J Pharmacol 238:303–309

    PubMed  CAS  Google Scholar 

  416. Watanabe T, Matsuhashi K, Shimada M et al. (1994) Reproductive toxicity studies of the new cognition-enhancing agent nefiracetam in rats and rabbits. Arzneim Forsch 44:239–242

    CAS  Google Scholar 

  417. Woodruff-Pak DS, Hinchliffe RM (1997) Mecamylamineor scopolamine-induced learning impairment: ameliorated by nefiracetam. Psychopharmacol 131:130–139

    CAS  Google Scholar 

  418. Yamada K, Nakayama S, Shiotani T et al. (1994) Possible involvement of the activation of voltage-sensitive calcium channels in the ameliorating effects of nefiracetam on scopolamine-induced impairment of performance in a passive avoidance task. J Pharmacol Exp Ther 270:881–892

    PubMed  CAS  Google Scholar 

  419. Ehrhardt G, Ruschig H (1972) Arzneimittel, VCH, Weinheim: Bd.I, S. 174

    Google Scholar 

  420. Hansch C (1990) Comprehensive Medicinal Chemistry, 1st Ed., Pergamon Press, Oxford, S. 701

    Google Scholar 

  421. Dictionary of organic compounds (1965) Eyre & Spootswoode Publ., London, S.2304

    Google Scholar 

  422. Mar31, S.29

    Google Scholar 

  423. Drugs Fut (1993) 18(4):324-326

    Google Scholar 

  424. Hattox SE, Noms SH, Riska PS, Silverstein HH, George RS, Johnstone JN, Hargrave KD, Grob PM (1992) Drugs Fut 17:887–889

    Google Scholar 

  425. Kelly TA (1996) US Pat, zit. nach CA 125:142791

    Google Scholar 

  426. Kelly TA, Terence A, Patel UR (1995) J Org Chem 60:1875–1877

    CAS  Google Scholar 

  427. Ple N, Turck A, Couture K, Queguiner G (1996) Synthesis S:838-842

    Google Scholar 

  428. Grozinger KG, Fuchs V, Hargrave KD, Mauldin S, Vitous J, Campbell S, Adams J (1995) J Heterocycl Chem 32:259–263

    CAS  Google Scholar 

  429. Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, FuchsVU, Mauldin SC, Vitous J et al. (1991) J Med Chem 34:2231–2241

    PubMed  CAS  Google Scholar 

  430. Norman MH, Minick DJ, Martin GE (1993) J Heterocycl Chem 30:771–779

    CAS  Google Scholar 

  431. Palladino DEH, Hopkins JL, Ingraham RH, Warren TC, Kapadia SR, Van Moffaert GJ, Grob PM, Stevenson JM, Cohen KA (1994) J Chromatogr A 676:99–112

    PubMed  CAS  Google Scholar 

  432. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411–1413

    PubMed  CAS  Google Scholar 

  433. Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 35:305–308

    PubMed  CAS  Google Scholar 

  434. Viraimune® Prescribing Information, Boehringer Ingelheim (1997) (online: http://www.viramune.com/Product-Info/FullPrescribinglnfo.html)

    Google Scholar 

  435. Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ (1993) Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 37:178–182

    PubMed  CAS  Google Scholar 

  436. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M (1995) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537–545

    PubMed  CAS  Google Scholar 

  437. Flieger M, Sedmera P et al. (1984) J Chromatogr 284:219–225, zit. nach CA (1984) 100:145058q

    CAS  Google Scholar 

  438. Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf

    Google Scholar 

  439. Trtik B (1987) Czech, zit. nach CA (1989) 110:13664j

    Google Scholar 

  440. Vachek J (1986) Czech, zit. nach CA (1987) 106:182777w

    Google Scholar 

  441. Neumann BW, Lauschner F (1979) Arzneim Forsch 29:1206

    CAS  Google Scholar 

  442. Fariello RG (1997) Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Functional Neurology, 12:221–225

    PubMed  CAS  Google Scholar 

  443. Saletu B, Anderer P, Semlitsch HV (1997) Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Dementia and Geriatric Cognitive Disorders, 8(Suppl. 1): 12–21

    PubMed  Google Scholar 

  444. Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, Wicke L, Neuhold A, Podreka I (1995) Nicergoline in senile dementia of Alzheimer type and multi-infarkt dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 11/.385–395

    Google Scholar 

  445. Mimori Y, Nakamura S, Yukawa M (1997) Abnormalities of acetylcholinesterase in Alzheimer’s disease with special reference to effect of acetylcholinesterase inhibitors. Behavioural Brain Research 83:25–30

    PubMed  CAS  Google Scholar 

  446. Carfagna N, Di Clemente A, Cavanus S, Damiani D, Gerna M, Salmoiraghi P, Cattaneo B, Post C (1995) Modulation of hippocampal Ach release by chronic nicergoline treatment in freely moving young and aged rats. Neuroscience Letters 197:195–198

    PubMed  CAS  Google Scholar 

  447. Carfagna N, Cavanus S, Damiani D, Salmoiraghi P, Fariello R, Post C (1996) Modulation of phosphoinostide turnover by chronic nicergoline in rat brain. Neuroscience Letters 209:189–192

    PubMed  CAS  Google Scholar 

  448. Herrmann WM, Stephan K, Gaede K, Apeceche M (1997) A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dementia and Geriatric Cognitive Disorders. 8:9–17

    PubMed  CAS  Google Scholar 

  449. Bottiger Y, Dostert P, Benedetti MS, Bani M, Fiorentini F, Casati M, Poggesti I, Alm C, Alvan G, Bertilsson L (1996) Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol 42:707–711

    PubMed  CAS  Google Scholar 

  450. Meilhac B, Montestruc F, Aubin F, Dhian F, Rouffy J (1997) Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication. Therapie 52:179–186

    PubMed  CAS  Google Scholar 

  451. Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P (1996) Pleuropulmonary changes induced by ergoline drugs. European respiratory J. 9:1013–1019

    CAS  Google Scholar 

  452. Clarke’s (1986) Isolation and Identification of Drugs in Pharmaceutics, Bodyfluids and Post Mortem Material, Pharmaceutical Press, London, S. 806–807

    Google Scholar 

  453. Mar31, S. 915

    Google Scholar 

  454. Salmi HA, Frey H (1974) Nicotinic acid plasma concentrations after ingestion of 1,3,4,6-tetranicotinoyl-fructofuranose (tetranicotinoylfructose, nicofuranose). Curr Ther Res Clin Exp 16:669–674

    PubMed  CAS  Google Scholar 

  455. Pankiewicz F (1965) Beitrag zur Therapie von Durchblutungsstörungen mit Tetranicotinoyl-fructofuranose (Nicofuranose). Ther Umsch 22:494–497

    PubMed  CAS  Google Scholar 

  456. Kujira T, Matsunaga I, Mori T, Nagano H, Ogasawa T, Shindo M, Sugano S, Takaku S (1980) US 4,200,640; zit. nach CA 93 (1980) P 132382f

    Google Scholar 

  457. Xu J, Zeng S, Dai S, Zheng X (1986) Yaoxue Tongbao 21:273–275

    CAS  Google Scholar 

  458. Schwende FJ, Lewis RC (1990) J Chromatogr 525:151–160

    PubMed  CAS  Google Scholar 

  459. Frampton J, Buckley MM, Fitton A (1992) Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 44:625–655

    PubMed  CAS  Google Scholar 

  460. Hamilton TC, Weston AH (1989) Cromakalim, Nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. General Pharmacol 20:1–9

    CAS  Google Scholar 

  461. Goldschmidt M, Landzberg BR, Frishman WH (1996) Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. J Clin Pharmacol 36:559–572

    PubMed  CAS  Google Scholar 

  462. Knigth C, Purcell H, Fox K (1995) Potassium channel openers: clinical applications in ischemic heart disease — overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 9(Suppl 2):229–236

    Google Scholar 

  463. Richer C, Pratz J, Mulder P, Mondot S, Giudicelli IF, et al. (1990) Cardiovascular and biological effects of K+ channel openers, a class of drug with vaosrelaxant and cardioprotective properties. Life Sciences 47:1693–1705

    PubMed  CAS  Google Scholar 

  464. Suryapranata H, Serruys PW, De Feyter PJ, Verdouw PD, Hugenholtz PG (1988) Coronary vasodilatory action after a single dose of nicorandil. Am J Cardiol 61:292–297

    PubMed  CAS  Google Scholar 

  465. Furukawa K, Itoh T, Kajiwara M, Kitamura K, Suzuki H (1981) Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea pig coronary arteries. J Pharmacol Exp Ther 218:248–259

    PubMed  CAS  Google Scholar 

  466. Nakae I, Quan L, Hashimot K, Sugimoto Y, et al. (1994) Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther 8:137–145

    PubMed  CAS  Google Scholar 

  467. O’Rourke ST (1996) KATP channel activation mediated nicorandil-induced relaxation of nitrate-tolerant coronary arteries. J Cardiovasc Pharmacol 27:831–837

    PubMed  Google Scholar 

  468. Larsen AI, Goransson L, Aarsland T, Tamby JF, et al. (1997) Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 134:435–441

    PubMed  CAS  Google Scholar 

  469. Tabone X, Funck-Bretano C, Billon N, Jaillon P (1994) Comparison of tolerance of intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers. Clin Pharmacol Ther 56:672–679

    PubMed  CAS  Google Scholar 

  470. Wolf DL, Jungbluth GL, Metztler CM, Froeschke MOE, et al. (1994) Acute effects of increasing doses of nicorandil on renal function in man. Int J Clin Pharmacol Ther 32:246–253

    PubMed  CAS  Google Scholar 

  471. Baumbach A, Braun U, Doring G, Haase KK, et al. (1995) Double-blind comparison on the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility. Cardiovasc Drugs Ther 9(Suppl 2):213–220

    PubMed  Google Scholar 

  472. Saito S, Mizumura T, Takayama T, Honye J, et al. (1995) Antiischemic effects of nicorandil during coronary angioplasty in humans. Cardiovasc Drugs Ther 9(Suppl 2):257–263

    PubMed  Google Scholar 

  473. Grover GJ (1997) Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Can J Physiol Pharmacol 75:309–315

    PubMed  CAS  Google Scholar 

  474. Robert E, Delye B, Aya G, Peray P, et al. (1997) Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart. J Cardiovasc Pharmacol 29:109–118

    PubMed  CAS  Google Scholar 

  475. Jaraki O, Strauss WE, Francis S, Loscalzo J, et al. (1994) Antiplatelet effects of a novel antianginal agent, nicorandil. J Cardiovasc Pharmacol 23:24–30

    PubMed  CAS  Google Scholar 

  476. Kaski JC (1995) Management of vasopastic angina — role of nicorandil. Cardiovasc Drugs Ther 9(Suppl 2):221–227

    PubMed  Google Scholar 

  477. Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ (1989) Pharmacokinetics of nicorandil. American J Cardiol 63:25J–33J

    CAS  Google Scholar 

  478. Witchitz S, Darmon JY (1995) Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 9(Suppl 2):237–243

    PubMed  Google Scholar 

  479. Dornow A, Wedekind G (1953) Arch Pharm (Weinheim) 286:338–344

    CAS  Google Scholar 

  480. Papadopoulos EP, Jarrar A, Issidorides CH (1946) J Org Chem 31:615–616

    Google Scholar 

  481. Nakamoto K, Martell AE (1959) J Am Chem Soc 81:5857–5863

    CAS  Google Scholar 

  482. Laviron É (1961) Bull Soc Chim Fr: 2325-2349

    Google Scholar 

  483. Dictionary of organic compounds, (1965) 4. Aufl. Eyre & Spottiswoode, London

    Google Scholar 

  484. Auterhoff H, Kovar KA (1985) Identifizierung von Arzneistoffen, 5.Aufl., Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, S. 59

    Google Scholar 

  485. Klosa J (1955) Arch Pharm (Weinheim) 288:426–427

    CAS  Google Scholar 

  486. Etablissements Clin-Byla, Fr M 8,197 (1973) zit. nach CA 78:58455

    Google Scholar 

  487. Etablissements Clin-Byla, Ger Offen 1.932.844 (1970) zit. nach CA 72:90493

    Google Scholar 

  488. Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 2880

    Google Scholar 

  489. Mousseron M (1968) Fr. 1.489.07; zit. nach CA (1968) 69:19154

    Google Scholar 

  490. Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 2256

    Google Scholar 

  491. Carron M, Jullien A, Julien T, Garozynska C (1963) Ann Pharm Franc 21:287–297

    PubMed  CAS  Google Scholar 

  492. Broquaire M, Guinebault PR (1981) J Liq Chromatogr 4:2039–2061

    CAS  Google Scholar 

  493. Tulus R, Gurkan T (1973) Univ Eczacilik Fak Mecm 9:63–76

    CAS  Google Scholar 

  494. Buisson Y, Larribaud J (1989) Therapie 44:123–26

    PubMed  CAS  Google Scholar 

  495. Bouree P Chaput JC, Krainik et al. (1989) Gastroent Clin Biol 13:469–72

    PubMed  CAS  Google Scholar 

  496. Ojasoo T (1987) Drugs Fut 12:763–770

    Google Scholar 

  497. Perronnet J, Girault P, Bonne C (1977) Ger Pat 2649925, zit nach CA 87: 85005z

    Google Scholar 

  498. Moguilewsky M, Fiet J, Tournemine C, Raynoud JP (1986) Pharmacology of an antiandrogen, anadron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem 24(1):139–146

    PubMed  CAS  Google Scholar 

  499. Pendyala L, Creaven PJ, Huben R, Tremblay D, Bertagna C (1988) Pharmacokinetics of Anadron in patients with advanced carcinoma of the prostate. Cancer Chemother Pharmacol 22(1):69–76

    PubMed  CAS  Google Scholar 

  500. Matveev BP, Bukharkin BV, Zhumagazin ZhD (1993) Lechenie antiandrogenami bol’nykh rakom predstatel’noi zhelezy s metastazami v kosti. Urol Nefrol Mosk (1):10–14

    PubMed  Google Scholar 

  501. Cozinet B, Thomas G, Thalabard JC, Brailly S, Schaison G (1989) Effects of a pure antiandrogen on gonadrotropin secretion in normal women and in polycystic ovarian disease. Fertil Steril 52(1):42–50

    Google Scholar 

  502. Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD (1990) A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 1; 66(5 Suppl):1074–1079

    CAS  Google Scholar 

  503. Janknegt RA (1993) Total androgen blockade with the use of orchiectomy and nilutamide (Anadron) or placebo as treatment of metastatic prostate cancer: Anadron International Study Group. Cancer 72(12 Suppl):3874–3877

    PubMed  CAS  Google Scholar 

  504. Bertagna C, De Gery A, Hucher M, Francois JP, Zanirato J (1994) Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 73(4):396–402

    PubMed  CAS  Google Scholar 

  505. Prostate Cancer Trialists’ Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346(8970):265–269

    Google Scholar 

  506. Asscheman H, Gooren LJ, Peereboom Wynia JD (1989) Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals experienees-with a novel androgen receptor blocker. Clin Exp Dermatol 14(5):361–363

    PubMed  CAS  Google Scholar 

  507. Harnois C, Malenfant M, Dupont A, Labrie F (1986) Ocular toxicity of Anadron in patients treated for prostatic cancer. Br J Ophthalmol 70(6):471–473

    PubMed  CAS  Google Scholar 

  508. Jonville AP, Diot E, Dutertre JP, Autret E (1992) Toxicité pulmonaire du nilutamide (Anadron). Bilan cooperatif des centres français de pharmacovigilance. Therapie 47(5):393–397

    PubMed  CAS  Google Scholar 

  509. Hammel P, Ducreux M, Bismuth E, Ladouch-Badre A, Benoit G, Buffet C, Ettiente JP (1991) Nilutamide-induced acute hepatitis. Gastroenterol Clin Biol 15(6–7):557

    PubMed  CAS  Google Scholar 

  510. Rouger-Barbier D, Delefosse D, Pamphile R, Goldfarb G (1989) Absence de manifestation clinique et biologique après absorption massive de nitulamide. J Toxicol Clin Exp 9(2):77–82

    PubMed  CAS  Google Scholar 

  511. Babany G, Tinel M, Letteron P, Freneaoux E, Berson A, Larrey D, Pessayre D (1989) Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450. Biochem Pharmacol 38(6):941–947

    PubMed  CAS  Google Scholar 

  512. Moore GGJ, Lappi LR, Can 996577, zit. nach CA (1977) 86:29488

    Google Scholar 

  513. Moore GGJ, Lappi LR, US 3856859, zit. nach CA (1975) 82:170368

    Google Scholar 

  514. Fernandez Otero GC, Carducci CN (1991) J Liq Chromatogr 14(8):1561–1573

    CAS  Google Scholar 

  515. Nonzioli A, Luque G, Fernandez C (1989) J High Resolut Chromatogr 12(6):413–416

    CAS  Google Scholar 

  516. Castoldi D, Monzani V, Tofanetti O (1988) J Chromatogr 425(2):413–418

    PubMed  CAS  Google Scholar 

  517. Magni E (1993) The effect of nimesulid on prostanoid formation. Drugs Suppl 1:10–14

    Google Scholar 

  518. Carr DP, Henn R, Green JR (1986) Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastrointestinal toxicity of non-steroidal anit-inflammatory drugs in rat. Agents Actions 18:374–375

    Google Scholar 

  519. Swingle KF, Moore GG, Grant TJ (1971) 4-nitro-2-phenoxymethansulfonanilide (R-805): a chemically novel antiinflammatory agent. Arch Int Pharmacodyn Ther 221(1):132–139

    Google Scholar 

  520. Swingle KF, Chang SF, Erickson EH (1978) Impaired metabolic handling of drugs in rats with arthritis induced by 6-sufonanilamidoindazole. Biochem Pharmacol 27(20):2395–2398

    PubMed  CAS  Google Scholar 

  521. Rossoni G, Berti F, Buschi A, Villa LM, Bella DD (1993) New data concerning the antianaphylactic and antihistaminic of nimesulide. Drugs 46 Suppl 1:22–28

    PubMed  CAS  Google Scholar 

  522. Maffei Facino R, Carini M, Aldini G, Saibene L, Macciocchi A (1993) Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model. Int J Tissue React 15(6):225–234

    PubMed  CAS  Google Scholar 

  523. Pelletier JP, Martel-Pelletier J (1993) Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 46 Suppl 1:34–39

    PubMed  CAS  Google Scholar 

  524. Verhoeven AJ, Tool AT, Kuijpers TW, Roos D (1993) Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils. Drugs 46 Stuppl 1:52–58

    PubMed  CAS  Google Scholar 

  525. Vane JR, Botting RM (1995) A better understanding of anti-inflammatory drugs based on isoforms of COX. Adv Prost Thromb Leuko Res 23:41–48

    CAS  Google Scholar 

  526. Famaey JP (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulid: An overview. Inflamm Res 46:437–446

    PubMed  CAS  Google Scholar 

  527. Ward A, Brogden RN (1988) Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs 36(6):732–735

    PubMed  CAS  Google Scholar 

  528. Schärli AF, Brühlhart K, Monti T (1990) Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation. J Int Med Res, 18(4):315–321

    PubMed  Google Scholar 

  529. Ambrosioni E (1986) Farmacologia della nimesulide. Attualita Terapeutica Internazionale 33:7

    Google Scholar 

  530. Bernareggi A (1993) The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs 46 Suppl 1:64–72

    PubMed  CAS  Google Scholar 

  531. Castoldi D, Monzani V, Tofanetti O (1988) Simultaneous determination of nimesulide and hydroxynimesulide in human plasma and urine by high-performance liquid chromatography. J Chromatogr 425(2):413–418

    PubMed  CAS  Google Scholar 

  532. Maffei Facino R, Carini M, Brambilla A, Casciarri I, Scareicabarozzi I, et al. (1989) Metabolism of nimesulide in man and radical scavenging activity of its main metabolites. 3rd Interscience World Congress on Antirheumatics, Analgesics, Immunomodulators, Montecarlo, March 15–18, Abstract Book, p.244

    Google Scholar 

  533. Reiner M, Magni E (1982) Efficacy and safety of nimesulide in the short-term treatment of rheumatoid arthritis. Curr Ther Res 31:906–912

    Google Scholar 

  534. Reiner M (1982) Nimesulide in the short-term treatment of osteoarthrosis: a pilot study for assessing the minimal effective dose. J Int Med Res 10(2):92–98

    PubMed  CAS  Google Scholar 

  535. Pochobradsky MG, Mele G, Beretta A, Montagnani G (1991) Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res 17(3):197–204

    PubMed  CAS  Google Scholar 

  536. Gallucci M, Toscani F, Mapelli A, Cantarelli A, Veca G, Scaricabarozzi I (1992) Nimesulide in the treatment of advanced cancer pain. Double-blind comparison with naproxen. Arzneimittelforschung 42(8):1028–1030

    PubMed  CAS  Google Scholar 

  537. Toscani F, Gallucci M, Scaricabarozzi I (1993) Nimesulide in the treatment of advanced cancer pain. Double-blind comparison with naproxen. Drugs 46 Suppl 1:156–158

    PubMed  Google Scholar 

  538. Reiner M, Massera E, Magni E (1984) Nimesulide in the treatment of fever: a double-blind, crossover clinical trial. J Int Med Res 12(2):102–107

    PubMed  CAS  Google Scholar 

  539. Rondel RK, Eberhardt R, Koch J, et al. (1984) Treatment of primary essential dysmenorrhoea with nimesulide in a double-blind crossover study. Curr ther Res 35:123–129

    Google Scholar 

  540. Pulkkinen MO (1987) Alternations in intrauterine pressure, menstrual fluid prostaglandin F levels, and pain in dysmenorrheic women treated with nimesulide. J Clin Pharmacol 27(1):65–69

    PubMed  CAS  Google Scholar 

  541. Lecomte J, Monti T, Pochobradsky MG (1991) Antipyretic effects of nimesulide in paediatric practice: a doubleblind study. Curr Med Res Opin 12(5):296–303

    PubMed  CAS  Google Scholar 

  542. D’Apuzzo V, Monti T (1992) Pilot study of the antipyretic and analgesic activity of nimesulide paediatric suppositories. Drugs Exp Clin Res 18(2):63–68

    PubMed  Google Scholar 

  543. Fossaluzza V, Montagnani G (1989) Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res 17(3):295–303

    PubMed  CAS  Google Scholar 

  544. Perucca E (1993) Drug interactions with nimesulide. Drugs 46 Suppl 1:79–82

    PubMed  CAS  Google Scholar 

  545. Steinhäuslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J (1993) Renal effects of nimesulide in furosemidtreated subjects. Drugs, 46 Suppl 1:257–262

    PubMed  Google Scholar 

  546. Auteri A, Blardi P, Bruni F, Domini L, Pasqui AL, Saletti M, Verzuri MS, Scaricabarozzi I, Vargui G, Di Perri T (1991) Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide. Int J Clin Pharmacol Res 11(5):211–217

    PubMed  CAS  Google Scholar 

  547. Baggio E, Maraffi F, Montalto C, Nava ML, Torti L, Caciarri I (1993) A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure. Drugs, 46 Suppl 1:91–94

    PubMed  Google Scholar 

  548. Ruhemann (1910) J Chem Soc: 1438-1449

    Google Scholar 

  549. Teeters, Shriner (1933) J Am Chem Soc 55:3026–3028

    CAS  Google Scholar 

  550. McCaldin (1960) Chem Rev 60:39–51

    CAS  Google Scholar 

  551. Schönberg, Singer (1978) Tetrahedron 34:1285–1300; Schönberg, Azzam (1993) J Chem Soc:1428-1430

    Google Scholar 

  552. Purvis (1911) J Chem Soc:1953-1960

    Google Scholar 

  553. Shiratsuchi M, Shimizu N, Shigyo H, Kyotani Y, Kunieda H, Kawamura K, Sato S, Akashi T, Nagakura M (Kowa Co., Ltd.) Eur Pat Appl 42299; Jpn K 8207481 und 82106619; zit. nach Thorpe PJ (1983) Drugs Fut 8:497-499

    Google Scholar 

  554. Shiratsuchi M, Kawamura K, Akashi T, Fujii M, Ischihama H, Uchida Y (1987) Chem Pharm Bull 35:632–641

    PubMed  CAS  Google Scholar 

  555. Shiratsuchi M, Kawamura K, Akashi T, Ishihama H, Nakamura M, Takenaka F (1987) Chem Pharm Bull 35:3691–3698

    PubMed  CAS  Google Scholar 

  556. Ward JE, Coles P, Cox H, Eisenhofer G, Angus JA (1992) Relationship between the symphatholytic action of nebivolol and hypotension. J Cardiovasc Pharmacol 20:115–124

    PubMed  CAS  Google Scholar 

  557. Adachi T, Hori S, Miyazaki K, Takahashi E, Nakagawa M, Udagawa A, Hayashi N, Aikawa N, Ogawa S (1995) Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Eur J Pharmacol 286:210–204

    Google Scholar 

  558. Sasage H, Nakazawa M, Arakawa M, Imai S (1995) Contribution of cyclic GMP generation to the relaxation by nipradilol in the rabbit aorta. Gen Pharmacol 26:85–91

    PubMed  CAS  Google Scholar 

  559. Lamping KG, Bloom EN (1995) Comparison of coronary microvascular response to nipradilol and nitroglycerin. Pharmacology 51:315–322

    PubMed  CAS  Google Scholar 

  560. Sugano S, Kawafune T, Suzuki T, Kubota M, Okajima T, Sumino Y, Akita H (1995) Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis. Am J Gastroenterol 90:788–793

    PubMed  CAS  Google Scholar 

  561. Yoshikawa T, Handa S, Akaishi M, Mitamura H, Ogawa S (1995) Beta-1-selectivity is not essential to achieve therapeutic efficacy with beta-blockade therapy for idiopathic dilated cardiomyopathy. Cardiology 86:217–223

    PubMed  CAS  Google Scholar 

  562. Bäckström R, Honkanen E, Pippuri A, Karisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Mannisto PT (1989) J Med Chem 32:841–846

    PubMed  Google Scholar 

  563. Taskinen J, Wikberg T, Ottoila P, Kanner L, Lotta T, Pippuri A, Bäckström R (1991) Drug Metab Dispos 19:178–183

    PubMed  CAS  Google Scholar 

  564. Wikberg T, Taskinen J (1993) Drug Metab Dispos 21:325–333

    PubMed  CAS  Google Scholar 

  565. Schultz E, Nissinen E (1989) Biochem Pharmacol 38:3953–3956

    PubMed  CAS  Google Scholar 

  566. Nissinen E, Linden IB, Schultz E, Kaakkola S, Männistö PT, Potho P (1988) Eur J Pharmacol 153:263–269

    PubMed  CAS  Google Scholar 

  567. Aho P, Linden IB, Nissinen E, Pohto P (1988) Dig Dis Sci 33:897

    Google Scholar 

  568. Aho P, Linden IB, Nissinen E, Pohto P (1988) Dig Dis Sci 33:905

    Google Scholar 

  569. Aho PA, Linden IB (1992) Scand J Gastroenterol 27:134–138

    PubMed  CAS  Google Scholar 

  570. Feimström G, Säfsten B (1994) Dig Dis Sci 39:1839–1842

    Google Scholar 

  571. Dibbern HW, Wirbitzki E (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf, Nr. 3087

    Google Scholar 

  572. Mar 29, S. 1595

    Google Scholar 

  573. Keller K, Greiner S, Stockebrand S (1990) Homöopathische Arzneinmittel, Govi-Verlag, Bd.2

    Google Scholar 

  574. Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2

    Google Scholar 

  575. Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wissenschaftl. Autorenverlag Leer/Ostfriesland: S. 238-239

    Google Scholar 

  576. DHU, Karslruhe (1994) S. 148-149

    Google Scholar 

  577. Voisin H (1969) Materia medica des hom. Praktikers, Haug Verlag Heidelberg: S. 586

    Google Scholar 

  578. Kakác B, Vejdelek ZJ (1974) Handbuch der photometrischen Analyse organischer Verbindungen, Verlag Chemie, Weinheim, S. 709

    Google Scholar 

  579. Medwick T (1961) Metal-Containing Organic Compounds. In: Higuchi T, Brochmann-Hanssen E (Hrsg.) Pharmaceutical Analysis, Interscience Publishers, New York London Sydney, S. 711–734

    Google Scholar 

  580. Mar 31, S. 1139

    Google Scholar 

  581. Lorenz W, Behnisch R, Mietzsch R (1948) U.S. 2:443,742, zit. nach CA 42:8822e

    Google Scholar 

  582. Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 1314

    Google Scholar 

  583. Petrow V, Sturgeon B (1954) J Chem Soc 570

    Google Scholar 

  584. Chephasaar (1991) Basisinformation Nitroxolin, S. 1-23

    Google Scholar 

  585. Von Rütte B, Delnon I (1968) Der chronische Harnweginfekt und seine Behandlung mit Nibiol, Schweiz Med Wochenschr 98:1864–1868

    Google Scholar 

  586. Brühl P (1983) Zur aktuellen Resistenzsituation von Erregern bei Harnwegsinfektionen, Therapiewoche 33:4084–4088

    Google Scholar 

  587. Bourlioux P, Amgar A (1988) Etude multicentrique de la surveillance de la résistance à sept antibiotiques de germes isolés d’infections urinaires, Sem Hôp Paris 64:86–90

    CAS  Google Scholar 

  588. Michel-Nguyen A, Nourrit J, Penand A, Nicoli RM (1986) Nitroxoline et antifongiques traditioneis. Comparaison de leur activité antifongique sur 238 souches de levures (+), Bull Soc Fr Mycol Méd 15:265–268

    Google Scholar 

  589. Rödel B (1987) 8-Chinolinole, ausgewählte klinisch interessierende Derivate. In: Kramer A, Weuffen W, Krasilnikow AP, Gröschel D, Bulka E, Rehn D (Hrsg.) Antibakterielle, antifungielle und antivirale Antiseptik — ausgewählte Wirkstoffe, Handbuch der Antiseptik, Bd. II/3, Volk u. Gesundheit, Berlin, S. 345–350

    Google Scholar 

  590. Dufour A, Bollack C (1979) De le pénétration de la Nitroxoline dans le parenchyme prostatique. Essai thérapeutique, J Urol Néphrol 3:207–212

    Google Scholar 

  591. Mrhar A, Kopitar Z, Kozjek F, Presl V, Karba R (1979) Clinical pharmacokinetics of nitroxoline, Int J Clin Pharmacol Biopharm 17:476–481

    PubMed  CAS  Google Scholar 

  592. Bergogne-Berezin E, Berthelot G, Muller-Serieys C (1987) Actualité de la Nitroxoline, Pathol Biol 35:873–878

    PubMed  CAS  Google Scholar 

  593. Dodat H, Chavrier Y, Dyon JF, AubertD, Galifer RB, Montupet P, Morisson-Lacombe G, Moscovici J, Valla J (1988) Etude clinique multicentrique comparative de la nitroxoline versus cotrimoxazole dans le traitement préventif de l’infection urinaire chez l’enfant, Gazette Méd 95:56–59

    Google Scholar 

  594. Lenzner A (1983) Orale Behandlung von Pilzerkrankungen des Harntraktes mit Nitroxolin, Therapiewoche 33:1735–1738

    Google Scholar 

  595. Sachse D (1984) Therapie chronisch-rezidivierender Harnwegsinfekte mit Nitroxolin, Therapiewoche 34:228–230

    Google Scholar 

  596. Cancet B, Amgar A (1987) Activité antifongique de la nitroxoline in vitro, Pathol Biol 35:879–881

    PubMed  CAS  Google Scholar 

  597. Frobert JL, Coupry A (1987) Traitement par Nibiol forte des infections des voies urinaires basses non compliquées chez la femme, Gazette Méd 94:71–74

    Google Scholar 

  598. Simon C, Stille W (1989) Antibiotikatherapie in Klinik und Praxis, 7. Aufl., Schattauer; S. 284

    Google Scholar 

  599. Kramer A, Rozsahegyil, Weuffen W (1985) Chronische Vergiftungen durch Antiseptika. In: Kramer A, Berencsi G, Weuffen W (Hrsg.) Toxische und allergische Nebenwirkungen von Antiseptika, Handbuch der Antiseptik, Bd. I/5, Volk u. Gesundheit, Berlin, S.217

    Google Scholar 

  600. NN (1988) Nitroxolin: Ermittlungen zur Wirksamkeit und Häufigkeit unerwünschter Wirkungen, Bundesgesundheitsblatt 31:281

    Google Scholar 

  601. Schneider H, Coper H (1968) Morphologische Befunde am Zentralnervensystem der Ratte nach Vergiftung mit Antimetaboliten des Nicotinamids (6-Aminonicotinsäureamid und 3-Acetylpyridin) und einem Chinolinderivat (5-Nitro-8-hydroxychinolin), Arch Psychiat Z Ges Neurol 211:138–154

    CAS  Google Scholar 

  602. Chephasaar (1991) Interne Untersuchungen. Briefl Mitt

    Google Scholar 

  603. Kommission der EG (1990) Vorschlag für eine Richtlinie des Rates zur Angleichung der Rechtsvorschriften der Mitgliedstaaten über kosmetische Mittel, Brüssel, 29.10.1990

    Google Scholar 

  604. Raduechel B, Skuballa W, Vorbrueggen H (1985) DE 3543991 Al, zit. nach CA (1987) 107:96503

    Google Scholar 

  605. Skuballa W, Raduechel B, Vorbrueggen H, Elgers Wet al. (1984) US 4444788 A, zit. nach CA (1984) 101:151672

    Google Scholar 

  606. Krause W, Jakobs U, Buckenauer R, Biese H (1990) Prostaglandins 40:283–296

    PubMed  CAS  Google Scholar 

  607. Konturek SJ, Brzozowski T, Drozdowicz D, Krzyzek E, Garlicki J, Majka J, Dembinski A, Stachura J, Amon I (1991) Eur J Pharmacol 195:347–357

    PubMed  CAS  Google Scholar 

  608. Konturek SJ, Konturek JW, Kwiecien N, Obrulowicz W, Olesky J, Hebzda Z, Arnon I (1991) Scand J Gastroenterol 26:231–236

    PubMed  CAS  Google Scholar 

  609. Konturek SJ, Kwiecien N, Obtulowicz W, Maczka J, Hebzda Z, Oleksy J (1991) Scan J Gastroenterol 26:1145–1151

    CAS  Google Scholar 

  610. Bilski J, Konturek SJ (1994) J Physiol Pharmacol 45:541–553

    PubMed  CAS  Google Scholar 

  611. Täuber U, Brudny-Klöppel M, Jakobs U, Madetzki C, Mahler m (1993) Eur J Clin Pharmacol 44:497–500

    Google Scholar 

  612. Booher RN, Pohland A (1975) J Med Chem 18:266–268

    PubMed  CAS  Google Scholar 

  613. Montzka TA, Matiskella JD, Partyka RA (1974) Tetrahedron Lett 1325-1328

    Google Scholar 

  614. Pohland A (Eli Lilly) (1962) U.S.-Pat. 3021360, zit. nach CA (1962) 57:P4594a

    Google Scholar 

  615. Billings RE, Booher R, Smits S, Pohland A, McMahon RE (1973) J Med Chem 16:305–306

    PubMed  CAS  Google Scholar 

  616. Lau DHM, Henderson GL (1976) J Chromatogr 129:329–338

    PubMed  CAS  Google Scholar 

  617. Kiang C, Campos-Flor S, Inturrisi CE (1981) J Chromatogr 222:81–93

    PubMed  CAS  Google Scholar 

  618. Mar31, S.57

    Google Scholar 

  619. Haefely W, Kyburz E, Gerecke M, Möhler H (1985) Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationship of their agonists and antagonists, Adv Drug Res 14:165–322

    CAS  Google Scholar 

  620. Klotz U (1984) Clinical pharmacology of benzodiazepines, Prog Clin Biochem Med 1:117–167

    CAS  Google Scholar 

  621. Affinito P, Monterubbianesi M, Primizia M et al. (1993) Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: Gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecol Endocrinol 7:259–266

    PubMed  CAS  Google Scholar 

  622. Bringer J (1992) Norgestimate: a clinical overview of a new progestin. Am J Obstet Gynecol 166:1969–1977

    PubMed  CAS  Google Scholar 

  623. Burkman RT (1995) The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98:130–136

    Google Scholar 

  624. Carr BR (1997) Re-evaluation of oral contraceptive classifications. Int J Fertil Womens Med, Suppl 1, 133–144

    Google Scholar 

  625. Genazzani AR, Petraglia F, Cleva M et al (1989) Norgestimate increases pituitary and hypothalamic concentrations of immunoreactive beta-endorphin. Contracept 40:605–613

    CAS  Google Scholar 

  626. Gidwani GP (1998) Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebocontrolled trial. Clin Pediatr 37:52

    Google Scholar 

  627. Hull ME, Moghissi KS (1986) Effects of norgestimate (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucus. Adv Contracept 2:71–77

    PubMed  CAS  Google Scholar 

  628. Kaplan B (1995) Desogrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 29:736–742

    PubMed  CAS  Google Scholar 

  629. Kuhl H (1996) Comparative pharmacology of newer progestogens. Drugs 51:188–215

    PubMed  CAS  Google Scholar 

  630. Kuhnz W, Blode H, Mahler M (1994) Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contracept 49:255–263

    CAS  Google Scholar 

  631. Lucky AW, Henderson TA, Olson WH et al. (1997) Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37:746–754

    PubMed  CAS  Google Scholar 

  632. Madden S, Back DJ (1991) Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. J Steroid Biochem Mol Biol 38:497–503

    PubMed  CAS  Google Scholar 

  633. Redmond GP, Olson WH, Lippman JS et al. (1997) Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89:615–622

    PubMed  CAS  Google Scholar 

  634. Samsioe G (1992) Introduction to steroids in the menopause. Am J Obstet Gynecol 166:1980–1985

    PubMed  CAS  Google Scholar 

  635. Schwingl PJ, Shelton J (1997) Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contracept 55:125–129

    CAS  Google Scholar 

  636. Shenfield GM, Griffin JM (1991) Clinical pharmacokinetics of contraceptive steroids. An update. Clinical Pharmacokinet 20:15–37

    CAS  Google Scholar 

  637. Sobel NB (1994) Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages? Obstet Gynecol Clin North Am 21:299–319

    PubMed  CAS  Google Scholar 

  638. Thorogood M (1998) Oral contraceptives and thrombosis. Curr Opin Hematol 5:350–354

    PubMed  CAS  Google Scholar 

  639. Vandenbroucke JP, Heimerhorst FM, Bloemenkamp KW et al. (1997) Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 177:887–891

    PubMed  CAS  Google Scholar 

  640. Wiegratz I, Jung-Hoffmann C, Gross W et al. (1998) Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contracept 58:83–91

    CAS  Google Scholar 

  641. Schnider O, Grüssner A (1951) Helv. Chim. Acta 271:2211–2217

    Google Scholar 

  642. Hansch C (1991) Comprehensive Medicinal Chemistry, Pergamon Press, Oxfords, Bd.6, S.722

    Google Scholar 

  643. Stead AH, Gill R, Wrigt T, Gibbs JP, Moffat AC (1982) Analyst 107:1106–1168

    PubMed  CAS  Google Scholar 

  644. Braun J (1914) Chem. Ber. 47:2312–2330

    Google Scholar 

  645. Speyer E, Walther L (1930) Chem. Ber. 63:852–855

    Google Scholar 

  646. Moffat AC (1986) Clarke’s Isolation and Identification of Drugs, 2nd Ed., The Pharmaceutical Press, London, S. 825

    Google Scholar 

  647. Jane I, McKinnon A, Flanangan RJ (1985) J Chromatogr 323:191–225

    PubMed  CAS  Google Scholar 

  648. Boerner U, Roe RL, Becker CE (1974) Detection, isolation and characterization of normorphine and norcodeine as morphine metabolites in man. J Pharm Pharmacol 26:393–398

    PubMed  CAS  Google Scholar 

  649. Gillan MG, Kosterliltz HW, Paterson SJ (1980) Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol 70:481–490

    PubMed  CAS  Google Scholar 

  650. Bockmühl M, Ehrhart G (1949) Liebigs Ann Chem 561:52–85

    Google Scholar 

  651. Beilstein, Erg. III/IV, Bd. 20/2, S. 914

    Google Scholar 

  652. Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 825

    Google Scholar 

  653. Beckett AH (1956) J Pharm Pharmacol 8:848–859

    PubMed  CAS  Google Scholar 

  654. Badiru SO, Jeffries TM (1988) J Pharm Biomed Anal 6:859–866

    PubMed  CAS  Google Scholar 

  655. Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin

    Google Scholar 

  656. Ebel S (1977) Handbuch der Arzneimittelanalytik, Verlag Chemie, Weinheim New York, S. 309–315

    Google Scholar 

  657. Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf, S. 2127

    Google Scholar 

  658. Zingales I (1968) J Chromatogr 34:44–51

    PubMed  CAS  Google Scholar 

  659. Knox JH, Jurand J (1975) J Chromatogr 103:311–326

    CAS  Google Scholar 

  660. Norheim G (1974) J Chromatogr 88:403–406

    PubMed  CAS  Google Scholar 

  661. Baldessarini RJ (1989) J Clin Psychiatry 50;117–126

    PubMed  CAS  Google Scholar 

  662. Baldessarini RJ (1985) Chemotherapy in psychiatry: Principles and practice. Cambridge, mass. Hardvard University Press: 130–223

    Google Scholar 

  663. Baldessarini RJ (1982) McLean Hosp J 7:1–27

    Google Scholar 

  664. Hegerl U, Müller HJ (1996) Psychopharmakotherapie 1:13–26

    Google Scholar 

  665. Morris JB, Beck AT (1974) Arch Gen Psychiatry 30:667–674

    PubMed  CAS  Google Scholar 

  666. Richelson E, Pfenning M (1984) Eur J Pharmacol 104:277–286

    PubMed  CAS  Google Scholar 

  667. Richelson E (1981) Tricyclic antidepressants: interaction with histamine and muscarinic acetylcholine receptors. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York: 53–73

    Google Scholar 

  668. Peroutika SJ, Snyder SH (1981) Interactions of antidepressants with neurotransmitter receptor sites. IN: Enna SJ, Malick JB, Richelson E (Hrsg.) Anitdepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York 75–90

    Google Scholar 

  669. Möller-Nielsen I (1980) Tricyclic antidepressants: General pharmacology. In: Born GVR, Farah A, Herken H, Welch AD (Hrsg.) Handbook of experimental pharmacology, Vol. 55/I. Hoffmeister F, Stille G (Hrsg.) Psychotropic agents Parti: Antipsychotics and antidepressants. Springer-Verlag, Berlin Heidelberg New Yrok:399–414

    Google Scholar 

  670. Shein K, Smith SE (1978) Br J Pharmacol 62:567–571

    PubMed  CAS  Google Scholar 

  671. Delini-Stula A (1993) Experimentelle und klinische Pharmakologie. In: Riederer P, Laux G, Pöldinger W (Hrsg.) Neuro-Psychopharmaka Bd. 3: Antidepressiva und Phasenprophylaktika. Springer-Verlag Wien 20–25

    Google Scholar 

  672. Mobley PL, Sulser F (1981) Down regulation of central noradrenergic receptor system by antidepressant therapies: Biochemical and clinical aspects. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants. Neurochemical, behavioral, and clinical perpectives. Raven Press, New York 31–51

    Google Scholar 

  673. Sulser F (1983) Psychopharmacol Bull 19:300–304

    PubMed  CAS  Google Scholar 

  674. Babington RG (1981) Neurophysiologic techniques and antidepressive activity. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven press, New York: 157–173

    Google Scholar 

  675. Gram LF, Overo KF (1975) Clin Pharmacol Ther 18:305–314

    PubMed  CAS  Google Scholar 

  676. Rubin EH, Biggs JT, Prescorn SH (1985) J Clin Psychiatry 46:418–424

    PubMed  CAS  Google Scholar 

  677. Pollock BG, Perel JM (1989) Can J Psychiatry 34:609–617

    PubMed  CAS  Google Scholar 

  678. Ziegler VE, Co BT, Taylor JR, Clayton PJ, Biggs JT (1976) Clin Pharmacol Ther 19:795–801

    PubMed  CAS  Google Scholar 

  679. Asberg M, Crönholm B, Sjöqvist F, Tuck D (1971) Br Med J 3:331–334

    PubMed  CAS  Google Scholar 

  680. Oliveira IR, Do-Prado-Lima PAS, Samuel-Lajeunesse B (1989) Psychiatr Psychobiol 4:43–60

    Google Scholar 

  681. Perry PJ, Pfohl BM, Holstad SG (1987) Clin Pharmacokinet 13:381–392

    PubMed  CAS  Google Scholar 

  682. Dahl ML, Nordin C, Bertilsson L (1991) Ther Drug Monit 13:189–194

    PubMed  CAS  Google Scholar 

  683. Brosen K (1990) Clin Pharmacokinet 18:220–239

    PubMed  CAS  Google Scholar 

  684. Coutts RT (1994) J Psychiatr Neurosci 19:30–44

    CAS  Google Scholar 

  685. Eichelbaum M, Gross AS (1990) Pharmacol Ther 46:377–394

    PubMed  CAS  Google Scholar 

  686. Dahl-Puustinen ML, Perry TL, Dumont G, von Bahr C, et al. (1989) Clin Pharmacol Ther 45:650–656

    PubMed  CAS  Google Scholar 

  687. Georgotas A, McCue RE, Cooper TB, Nagachandran N, et al. (1988) Arch Gen Psychiatry 45:929–932

    PubMed  CAS  Google Scholar 

  688. Roszinsky-Köcher G (1995) Psychopharmakotherapie 2:15–18

    Google Scholar 

  689. Perry PJ, Browne JL, Alexander B, Tsuang MT, et al. (1984) Clin Pharmacokinet 9:555–563

    PubMed  CAS  Google Scholar 

  690. Möller HJ, Schmauß M (1996) Arzneimitteltherapie in der Psychiatrie. Wissenschaftl. Verlagsgesellschaft Stuttgart

    Google Scholar 

  691. Benkert O, Hippius H (1996) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York

    Google Scholar 

  692. Eckert A, Reiff J, Müller W (1989) Psychopharmakotherapie 5:8–18

    Google Scholar 

  693. Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders: In: Goodman GA, Rall TW, Nies AS, Tylor P (Hrsg.) Goodman and Gilman’s The pharmacological basis of therapeutics. 8th edition. Macmillan, New York 383–435

    Google Scholar 

  694. Thomann P, Hess R (1980) Toxicology of antidepressants. In:. Born GVR, Farah A, Herken H, Welch AD (Hrsg.) Handbook of experimental pharmacology, Vol. 55/I. Hoffmeister F, Stille G (Hrsg.) Psychiotropic agents Part I: Antipsychotics and antidepressants. Springer-Verlag, Berlin Heidelberg New York:527–549

    Google Scholar 

  695. Vohra J, Burrows G, Hunt D, Slowmann G (1975) Eur J Cardiol Excerpta Medica 3:219–227

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von Bruchhausen, F. et al. (1999). N. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58388-9_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63569-4

  • Online ISBN: 978-3-642-58388-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics